Prerpints.org logo
Preprint
Review

Current Insights in Prolactin Signaling and Ovulatory Function in Health and Disease

Altmetrics

Downloads

228

Views

82

Comments

0

A peer-reviewed article of this preprint also exists.

This version is not peer-reviewed

Submitted:

11 January 2024

Posted:

11 January 2024

You are already at the latest version

Alerts
Abstract
Prolactin (PRL) is a pleiotropic hormone released from lactotrophic cells of the anterior pituitary gland that also originates from extrapituitary sources and plays an important role in regulating lactation in mammals, as well as other actions. Acting in an endocrine and paracrine/autocrine manner, PRL regulates the hypothalamic-pituitary-ovarian axis, thus influencing the maturation of ovarian follicles and ovulation. This review provides a detailed discussion of the current knowledge on the role of PRL in the context of ovulation and ovulatory disorders, particularly with regard to hyperprolactinemia, which is one of the most common causes of infertility in women. Much attention has been given to the PRL structure and the PRL receptor (PRLR), as well as the diverse functions of PRLR signaling under normal and pathological conditions. The hormonal regulation of the menstrual cycle in connection with folliculogenesis and ovulation, as well as the current classifications of ovulation disorders, are also described. Finally, the state of knowledge regarding the importance of TIDA (tuberoinfundibular dopamine), KNDγ (kisspeptin/neurokinin B/dynorphin) and GnRH (gonadotropin-releasing hormone) neurons in PRL- and kisspeptin (KP)-dependent regulation of the hypothalamic-pituitary-gonadal (HPG) axis in women is reviewed. Based on this review, a rationale for influencing PRL signaling pathways in therapeutic activities accompanying ovulation disorders is presented.
Keywords: 
Subject: Medicine and Pharmacology  -   Reproductive Medicine

1. Introduction

Reports on the lactogenic (prolactogenic) activity of extracts from the anterior pituitary gland of cows first appeared in 1928 in the publication by P. Stricker and F. Grueter from the laboratory of Bouin at the University of Strasbourg, France [1,2]. Stimulation of lactation in rabbits via the injection of pituitary extracts was also confirmed in pigeons by O. Riddle, R.W. Bates and S.W. Dykshorn at the Cold Spring Harbor Laboratory on Long Island, New York, USA [3]. The latter team of authors made significant contributions to the identification, isolation and purification of a compound that acts as a polypeptide hormone and a tetrahelical cytokine, which was referred to as prolactin (PRL) because of its role in lactation [4,5].
After many years of intensive research, it is now known that PRL has a wide range of other diverse functions in the body [6,7,8,9] influencing not only the reproductive system [8,9,10,11,12,13,14] but also growth and development [15], metabolism [16,17,18,19], electrolyte transport [20], the integumentary system [21,22], behavior [23], the immune system [24,25,26] and carcinogenesis [27,28,29]. PRL exerts these versatile actions by acting on its receptor (PRLR), which is an archetype member of the class I cytokine receptor family [30,31,32].
Moreover, the development of precise bioassay methods has made it possible to discover that, under the control of the hypothalamus, anterior pituitary lactotrophs are not the only source of PRL. The multiple extrapituitary sites at which PRL is expressed and secreted in humans include the brain, endothelial cells, immune cells, decidua and ovarian tissue [9,33]. Pituitary PRL expression has been shown to be dependent on the Pit-1 transcription factor, which is a member of the Pit-Oct-Unc (POU) homeodomain protein family, whereas the extrapituitary PRL gene promoter that allows for PRL expression in several nonpituitary cells and tissues has dissimilar activity to the pituitary promoter, with Pit-1-independent activity and responsiveness to different regulators of gene expression [34].
The latter of the listed locations indicates that the human ovary not only serves as a target for endocrine PRL but also as a site of local PRL hormone production [9,35,36]. In ovarian tissue, PRL is expressed in both the antral follicle, theca and granulosa layers and is produced by granulosa cells [5,36,37,38]. Moreover, by acting locally as an autocrine or paracrine cytokine, this hormone is an important modulator of key processes such as follicular growth and development, angiogenesis, ovulation and steroidogenesis [13,39]. Despite the lack of consensus regarding their detailed comprehensive classification, ovulatory disorders are among the leading causes of infertility [40,41]. Therefore, abnormal PRL activity, both in the blood and at the level of ovarian tissue, can cause infertility due to the mechanism of anovulation or infrequent ovulation (oligo-ovulation) secondary to hormonal imbalances [42,43,44].
The aim of this review is to provide a comprehensive presentation of the current state of knowledge on the role of PRL in the process of ovulation and its disorders. Thus, a rationale for influencing PRL signaling pathways in therapeutic activities accompanying ovulation disorders is outlined.

2. Prolactin (PRL)

2.1. Structure

PRL is a globular protein hormone composed of a single-chain polypeptide with a molecular weight of 23 kDa that contains 199 amino acids in humans. There are three intramolecular disulfide bonds between the following six cysteine residues in the human PRL chain: Cys4-Cys11, Cys58-Cys174 and Cys191-Cys199 (Figure 1A) [5].
Analysis of the secondary structure of the PRL molecule showed that 50% of the length of the amino acid chain is arranged in α-helices, whereas the remaining part of the chain forms loops. According to the model of the tertiary structure of PRL, four long α-helices with four α-helical domains and two receptor binding sites are arranged in an antiparallel fashion (Figure 1B) [5,45].
Amino acid sequence homology with the human genome shows considerable species variation, ranging from 97% homology in primates to only 56% homology between primates and rodents [5,46]. In humans, PRL is structurally similar to growth hormone (GH) and human placental lactogen (hPL, also known as human chorionic somatotropin [hCS]). Together, these proteins form the "PRL/GH/hPL" family, which is characterized by a conserved helix bundle protein composition (Group I of the helix bundle protein hormones); consequently, PRL has similar biological activities to its representatives [47,48]. The genes encoding PRL, GH and hPL were generated as a result of the evolution of the common ancestor gene, which consisted of duplication of this gene. In humans, a single gene encoding PRL is located on chromosome 6 [49]. This gene is 10 kb in length and contains 5 exons and 4 introns. The PRL gene transcription process is regulated by two independent promoter regions: the proximal region that controls pituitary-specific expression and the more upstream 5,000-bp region that directs extrapituitary expression of PRL [50]. Preprolactin, which is a protein 2–3 kDa heavier than mature PRL, represents the initial product of PRL mRNA translation, from which PRL is produced after removal of the 28-amino acid signal peptide by proteolytic cleavage [5,7].
In humans, as in animals, many variants of the structure of the PRL molecule have also been described; these variants occur in small, often trace amounts as a result of alternative splicing of the primary transcript, as well as proteolytic cleavage and other posttranslational modifications (e.g., dimerization and polymerization, phosphorylation, glycosylation, sulfation and deamidation) of the amino acid chain [46,51]. These modifications indicate that, in addition to the monomeric form of PRL, in the human body, PRL also occurs as a dimer (molecular weight [MW] of 48-56 kDa) composed of glycosylated monomers and in the form of macro-PRL or big-big PRL (MW >150 kDa) composed of antigen-antibody complexes of monomeric PRL and immunoglobulin (most commonly, IgG) [52,53]. In a healthy person, monomeric PRL is the predominant form of circulating PRL and accounts for 85% of the total immunoreactive PRL, whereas dimeric PRL and macro-PRL each account for approximately 5-10% of the total PRL in the blood [53]. It should be noted that routine tests cannot distinguish between the three forms of PRL, which may be important in diagnosing disorders of PRL production [54,55,56].

2.2. Prolactin receptor (PRLR)

PRLRs belong to the lactogen/hematopoietic cytokine receptor superfamily; additionally, as an archetype member of the class I cytokine receptor family that comprises systemic receptors with fundamental effects in the body, they play key roles in biology and as potential therapeutic targets. The same group of receptors as PRLRs, which consists of the simplest cytokine receptors, also includes the GH receptor, the interleukin-2 receptor (IL-2R), the erythropoietin receptor (EPOR) and the thrombopoietin receptor (TpoR, also known as MPL) [28,57]. Therefore, even with lower affinity, the PRLR can bind and be activated by hPL, GH, IL-2, EPOR and TpoR [31]. PRLR lacks an intrinsic kinase domain but possesses a Janus kinase 2 (JAK2)-associated region. Therefore, the receptor chain is dependent on the associated kinases to transduce phosphorylation-based signaling cascades. Upon PRL stimulation, the PRLR transduces signals through the activation of JAK2, thus leading to the phosphorylation of JAK2 [58].
The human PRLR gene is located at chromosomal region 5p14-p13. The genomic size of the human PRLR gene exceeds 200 kb, and the gene contains 11 exons, including six noncoding exons 1 that are alternatively spliced to a common noncoding exon 2, as well as exons 3-10 that encode the full-length activating long form of the receptor [59,60]. As a transmembrane receptor, the PRLR is composed of three main regions: the extracellular, transmembrane (a single transmembrane-spanning domain) and intracellular (cytoplasmic) regions. The extracellular region comprises two fibronectin type III domains known as D1 and D2. The WSXWS motif in D2, which is a generic cytokine class I receptor, acts as a molecular switch during ligand-bound activation of the PRLR [61]. Conversely, proline-rich sequence-mediated JAK2 association with the PRLR occurs in the intracellular domain. This JAK2/PRLR interaction is essential, although it alone cannot induce signal transduction through the Box-1/Box-2 subdomains. Further interaction of Box-1 with JAK2 and SRC family kinases (e.g., Fyn and c-Src) is required [62,63].
The long form of the PRLR may regulate signal transduction by exploiting the properties of the PRLR intracellular domain, which is intrinsically highly unstructured/disordered and binds to negatively charged lipids of the inner plasma membrane through conserved motifs resembling immune receptor tyrosine-based activation motifs [64]. Such lipid association of the PRLR intracellular domain is not accompanied by induced folding and is independent of specific tyrosine phosphorylation [64,65].
Intermediate and various short forms result from alternative splicing, variable promoter usage or other posttranscriptional (but unlikely) posttranslational modifications. Sequences from exon 11 are present only in the short forms of the receptor S1a and S1b and their respective variants [66,67]. Such proteome diversity in the PRLR results from the fact that, although many PRLR isoforms perform the same or similar biological roles, some of these isoforms have unique functions. Moreover, human PRLRs are located not only in the cell membrane but also in the cytosol (a soluble isoform) and, surprisingly, in cellular structures such as endosomes, the Golgi apparatus and lysosomes (here, they are presumably a degraded form of the receptor) [60,64,68]. All of the soluble forms of PRLR lack transmembrane and cytoplasmic regions [69,70]. A schematic illustration of the most common isoforms of human PRLR is included in Figure 2.

2.2.1. PRLR receptor signaling

PRLRs are expressed in a wide but varied range of human cells and tissues throughout an individual’s lifetime, starting from the preimplantation stage of the embryo and continuing further during intrauterine embryogenesis [6,71]. The binding of a PRL molecule produced in the pituitary or from extrapituitary sources to the extracellular ligand-binding domain of the PRLR initiates the signaling pathway within a systemic or local range, respectively. This also applies (to varying degrees and depending on the specific physiological or pathological conditions) to partial agonists of the PRLR (e.g., hPL, GH and IL-2) [31]. Studies have also shown that the binding affinity of human PRLR for nonhuman PRL is lower than that for human PRL [72]. Among the PRLR isoforms, the signaling pathways associated with the long form of the receptor are the most comprehensively characterized to date [68].
In canonical signaling, ligand binding to the PRLR results in stimulation of the tyrosine kinase activity of JAK2; moreover, with the exception of the short isoform of the receptor, multiple tyrosine residue phosphorylation within the PRLR occurs in the following ways. ❶ Subsequent activation of signal transducer and activator of transcription (STAT) proteins, particularly STAT5 (JAK2/STAT5 signaling), thus enforcing further downstream signaling [73,74]. Next, the tyrosine-phosphorylated STAT complex dissociates from the receptor, dimerizes and translocates into the nucleus, where it binds to the promoters of target genes. Although the JAK/STAT pathway is considered one of the major downstream pathways for cytokine receptor signaling, PRL also activates ❷ the Ras kinase/Raf kinase/mitogen-activated protein kinase/extracellular signal-regulated kinase ½ (Ras/Raf/MAPK/ERK1/2) pathway [75,76] and ❸ the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3-Kinase/AKT/mTOR) [76,77] downstream signaling pathway. In addition, in the absence of a physical association with STAT5a, ❹ signaling through the transcription factors RUSH-1α, RUSH-1β and SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A, member 3 (RUSH/SMARCA3), has been identified (Figure 3) [78].
This diversity of signaling pathways corresponds to the numerous functions of PRL, which are associated with both physiological states and play important roles in the pathomechanism of diseases, especially endocrine disorders [6,7,9]. Moreover, these key PRL-mediated signaling pathways are integrated. The differences in the functions of PRLR according to the pleiotropic nature of PRL and other PRLR agonists are presented under selected physiological and pathological conditions in Figure 4. A detailed discussion of these activities, apart from those directly related to ovulation, is beyond the scope of this review.

3. Ovulation

In women, ovulation is a phase in the menstrual cycle when the rupture of the dominant follicle within one of the ovaries leads to the release of the egg (the secondary oocyte or an oocyte arrested in meiosis II at the stage of metaphase II), which enters the lumen of the fallopian tube and creates a chance for fertilization in the presence of fertile sperm [14,113]. This physiological process occurs around day 14 of a 28-day menstrual cycle (or generally at approximately 2 weeks before the onset of menstruation) in women of reproductive age, i.e., from menarche to menopause (roughly from ages 12 to 49 years). Typically, human ovaries produce a single dominant follicle that is approximately 25 mm in diameter and contains approximately 50 million granulosa cells and 7 ml of follicular fluid at the time of ovulation. For ovulation to occur during each menstrual cycle, the ovarian follicle (or a Graafian follicle), which becomes the dominant follicle as a result of a highly selective process, must undergo all stages of folliculogenesis (recruitment, selection and ovulation) within a strictly defined time frame (Figure 5) [114,115,116,117,118,119,120,121,122,123], including those related to gene expression (Table 1.).
The pool of ovarian follicles, numbering approx. 150,000 during a woman's puberty, is subject to recruitment and selection processes leading to the development of the dominant Graafian follicle, which undergoes ovulation. It is worth noting that while the cyclical, gonadotropin-dependent recruitment of the early antral follicles takes place over 14-day periods (follicular phase), reaching this stage through the earlier stages of folliculogenesis (gonadotropin-independent in the case of primordial follicles and gonadotropin-responsive in the case of secondary follicles) takes much longer. The initiation of the menstrual cycle during puberty and its subsequent course are determined by the variable, pulsatile secretion of gonadoliberin (GnRH - gonadotropin-releasing hormone) from the hypothalamus. GnRH stimulates the production and secretion of gonadotropins (FSH – follicle-stimulating hormone and LH – luteinizing hormone) in the anterior pituitary gland (adenohypophysis), which in turn stimulate the development of ovarian follicles and the production of ovarian steroids by thecal and granulosa cells (GC): estrogen (predominantly estradiol – E2) and progesterone (P4). The negative feedback mechanism within the hypothalamic-pituitary-ovarian (HPO) axis plays a key role in regulating the levels of all hormones that control the menstrual cycle. However, there is an exception, when rising estradiol (E2) in the middle of the menstrual cycle paradoxically "switch" from being inhibitory on GnRH secretion ("negative feedback") to stimulating GnRH release ("positive feedback"), resulting in a surge in GnRH secretion and a downstream LH surge that triggers ovulation. The onset of LH surge usually precedes ovulation by 36 hours, whereas the peak serum level of LH occurs 10-12 hours before ovulation. Among the regulatory factors of the HPO axis negative feedback, the heterodimeric proteins produced by ovarian follicles inhibin A (αβA, InhA) and B (αβB, InhB) play a significant role. During the normal menstrual cycle, serum inhB levels are lowest in the early follicular phase, reach a mid-cycle peak coincident with decrease in FSH concentration and the preovulatory LH surge, and decrease during the luteal phase. Conversely, InhA concentrations are low during the selection and development of a dominant follicle, increase rapidly during ovulation, and are maximal during the mid-luteal phase. Changes in sex hormone concentrations are accompanied by cyclic changes in the endometrium (not shown in the figure), which enable implantation of the blastocyst after oocyte' fertilization or repetition of the cycle with the separation and expulsion of the functional layer of the uterine mucosa (onset of menstruation).
The mechanisms regulating the selection of antral ovarian follicles are poorly understood and are thought to rely on low estrogen levels, a decrease in follicle-stimulating hormone (FSH) levels and FSH receptor (FSHR) expression on the surface of granulosa cells. It has been assumed that a follicle capable of maximum expression of FSHR is able to maintain growth and becomes dominant in a given cycle [128,129]. However, such assumptions have not been confirmed under in vitro conditions, wherein apoptosis of human granulosa cells (hGLC) and transfected cell lines is induced by high doses of FSH or FSHR overexpression, whereas estrogens induce antiapoptotic signals via nuclear and a G protein-coupled estrogen receptor (GPER). Therefore, in vitro data suggest that antral follicle selection may be driven by underestimated, FSH-FSHR-dependent apoptotic signals due to transient maximization of FSHR expression and overload of cAMP signaling, thus prevailing on estrogen-dependent signals [130,131,132].
It is generally agreed in humans that a selected follicle becomes dominant at approximately one week before ovulation; specifically, this occurs as early as at 5 to 7 days of the cycle, at a time when the follicular diameter is approximately 10 mm. Only in the dominant follicle can FSH be detected at this point in time, which is also accompanied by a significant level of estradiol in the follicular fluid [121,122].
The remaining follicles that are recruited in a given cycle undergo atresia, the main mechanism of which in mammals involves programmed cell death (apoptosis). Therefore, follicular atresia is a physiological phenomenon that allows for the regulation of the number of follicles growing within a given pool by the crosstalk between cell death and cell survival signals. Accordingly, the fate of the individual follicle (growth to ovulation or inhibited growth with subsequent atresia) is dependent on a precise balance in the expression of specific receptors (mainly for endocrine hormones and gonadotropins) and the action of intraovarian factors (such as gonadal steroids, cytokines and growth factors) regulating follicular cell proliferation, growth and differentiation, as well as those promoting apoptosis. It is estimated that in each ovulatory cycle, the average ovary loses 1,000 follicles during the process of selecting a dominant follicle that will be released. Therefore, the total pool of follicles must be sufficiently large [133,134].
Indeed, the fetal ovary at the twentieth week of gestation contains 6-7 million oocytes, which results from the mitosis of approximately 500 to 1,300 primordial germ cells; this theoretically represents the entire cohort of oocytes capable of participating in reproduction during a woman’s lifetime [135]. These germ cells subsequently begin meiosis and arrest at meiotic prophase 1, wherein they form germ cell cysts and, ultimately, primordial follicles. Consisting of an oocyte surrounded by a single layer of cuboidal granulosa cells that initiates follicle development, primordial follicles are the first class of follicles that develop in mammalian ovaries. The process of follicular recruitment begins soon after this time point and proceeds continuously in both gonadotropin-independent (before puberty) and gonadotropin-dependent (after puberty) manners. Consequently, the number of follicles in the ovaries decreases to approximately 500,000 at birth, 150,000 at puberty and 1,000 at menopause [136]. Thus, out of the entire pool of ovarian follicles that are present on the day of the woman’s birth, ovulation will increase in only 0.1% of patients, whereas ovulation will increase in 99.9% of patients throughout the process of follicular atresia [137,138]. The continuity of folliculogenesis means that an active ovary always contains follicles in various stages of development [139].
The luteal phase occurs in the second half of the menstrual cycle, wherein it starts immediately after ovulation. This phase is usually 14 days long in most women. After the oocyte with cumulus cells is released from the ovulating follicle, the remaining granulosa cells continue to enlarge, become vacuolated, and begin to accumulate a yellow pigment known as lutein. Luteinized granulosa cells with newly formed theca-lutein cells and surrounding stroma give rise to a new structure known as the corpus luteum. The primary hormone produced by this transient endocrine organ is progesterone; however, it also produces inhibin A and estradiol. The primary function of the corpus luteum is to prepare the estrogen-primed endometrium for implantation of the fertilized ovum. This transformation of the endometrium is known as decidualization. In contrast to most mammals, decidualization of the human endometrium does not require embryo implantation. Instead, this process is driven by the postovulatory rise in progesterone levels and increasing local cAMP production [140]. Eight or nine days after ovulation, approximately around the time of expected implantation, peak vascularization is observed within the corpus luteum. This time period also corresponds to peak serum levels of progesterone and estradiol [117]. The lifespan of the corpus luteum depends upon continued LH support. Corpus luteum function declines by the end of the luteal phase, unless human chorionic gonadotropin (hCG) is produced during a pregnancy. If pregnancy does not occur, the corpus luteum undergoes luteolysis under the influence of estradiol and prostaglandins, during which a scar tissue known as the corpus albicans is formed [117]. In response to decreasing progesterone levels, spontaneous decidualization causes menstrual shedding and cyclic regeneration of the endometrium.

3.1. Hormonal regulation of ovulation

In addition to menstrual bleeding, ovulation is the most crucial element of fluctuations in hormonal balance; this process is repeated cyclically every 28 days (with a range of 21-40 days) and is referred to as the menstrual cycle. Occurring during the course of the menstrual cycle, the morphological changes in the ovaries leading to ovulation and the formation of the corpus luteum, as well as functional changes in the endometrium that enable blastocyst implantation in the event of fertilization of the ovum, are primarily regulated by hormones [141,142,143]. The pulsatile secretion of gonadotrophin-releasing hormone (GnRH) from the hypothalamus (under the control of the kisspeptin-neurokinin B-dynorphin [KNDγ] pathway) stimulates the anterior pituitary to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which correspondingly stimulate the development of ovarian follicles and the production of the ovarian steroids estrogen (predominantly estradiol) and progesterone (P4) [143,144,145,146]. A negative feedback mechanism within the hypothalamic-pituitary-ovarian (HPO) axis is crucial for the control and regulation of the menstrual cycle, particularly during the following three phases: follicular (which begins with menstrual bleeding), ovulatory, and luteal phases. However, there is an exception in females, wherein rising estradiol (E2) during the middle of the menstrual (or estrous) cycle paradoxically "switches" from being inhibitory on GnRH secretion ("negative feedback") to stimulating GnRH release ("positive feedback"), thus resulting in a surge in GnRH secretion and a downstream LH surge that triggers ovulation (Figure 6B) [147,148]. Additionally, the granulosa cells of the growing follicle secrete a variety of peptides that may play an autocrine/paracrine role in stimulating follicles (activins), thus inhibiting the development of adjacent follicles (e.g., inhibins and follistatin) or suppressing/unsuppressing the biosynthesis of FSH (inhibins vs. activins) [149,150,151,152]. The luteal phase of the cycle is relatively constant in all women, with a duration of 14 days. The variability of cycle length is usually derived from varying lengths of the follicular phase of the cycle, which can range from 10 to 16 days [117]. The general characteristics of the main endocrine hormones involved in the menstrual cycle and their importance during the process of ovulation are summarized in Table 2.
Importantly, all ovarian hormones that regulate the course of the menstrual cycle are synthesized under precisely defined conditions and time frames and act in an autocrine and paracrine manner. A comprehensive understanding of the mechanisms of influence at this level in physiological states and disorders (e.g., ovulation) requires further research [130,192,193,194].

3.2. Mechanism of follicle rupture during ovulation

The initial hypothesis that the rupture of the wall of the ovulating follicle occurs as a result of an increase in intrafollicular pressure has not been confirmed by different studies. Despite a significant and rapid increase in the volume of follicular fluid before ovulation, which is mainly due to the inflow of fluid from the extravascular space, no significant changes in intrafollicular pressure have been detected at that time [195].
Therefore, it is important that the preovulatory surge in gonadotropins (primarily LH) triggers a series of changes in the wall of the dominant follicle, the enzymatic degradation of which leads to rupture and determines the extrusion of the oocyte. Therefore, the assessment of the molecular mechanisms of follicle wall rupture during ovulation has focused on creating a model of interconnected signaling networks that initiate a proteolytic enzyme cascade that has a local effect. Many mediators of these LH-induced signaling cascades are associated with inflammation, including the production of mediators of the inflammatory response by granulosa and theca cells, such as steroids, prostaglandins, chemokines, and proteolytic enzymes (e.g., collagenase and plasmin) [173]. It has been demonstrated that granulosa cells in vivo produce increasing amounts of plasminogen activator as ovulation approaches and that the enzyme is solely produced by cells obtained from follicles destined to ovulate [196]. The production of plasminogen activator is regulated by gonadotropins [196,197].
The concentrations of prostaglandins E and F and hydroxyeicosatetraenoic acid (HETE) reach a peak in the follicular fluid just prior to ovulation [198,199].
Prostaglandins may stimulate both proteolytic enzymes and oocyte release by inducing smooth muscle fiber contractions within the ovary, whereas HETE may stimulate angiogenesis and hyperemia [117,199]. The point at which the dominant follicle is closest to the ovarian surface where digestion and subsequent rupture of the wall occur is known as the stigma.
In the context of the obvious similarities between ovulation and the inflammatory response, it is worth noting that at the level of ovarian follicles, PRL (which is also locally produced in the ovarian tissue) acts both as a hormone (endocrine and paracrine) and as a proinflammatory cytokine [5,200]. Thus, under certain conditions, the expression of PRLRs plays both pro- and anti-gonadal roles in the regulation of ovarian functions, including ovulation. For example, PRL may inhibit ovulation by stimulating granulosa cell apoptosis or promote ovulation by triggering a cascade of proteolytic processes in the wall of the ovarian follicle. However, neither the pattern of expression of PRLRs nor its regulatory mechanisms during follicle development have been clearly defined [201,202].

3.3. Ovulatory disorders

The term "ovulatory disorders" describes a set of abnormalities that occur continuously or intermittently, thus resulting in the absence of ovulation (anovulation) or its infrequent, irregular occurrence (oligoovulation) [203]. During oligoovulation, the menstrual cycle is typically longer than normal (21 to 35 days), thus resulting in eight or fewer menstrual periods per year. In addition to abnormal uterine bleeding, ovulatory disorders may disappear in some cases. Ovulatory disorders, which typically result from episodic or chronic dysfunction of the hypothalamic–pituitary–ovarian (HPO) axis, represent a major cause of infertility, as the lack of an optimal quality oocyte that is regularly released every month significantly reduces the chances of fertilization. Anovulation and oligoovulation are estimated to constitute 25% of the known causes of female infertility [204,205].
Although there are numerous known causes and contributors to ovulatory disorders, the entire spectrum of mechanisms of pathogenesis remains to be fully elucidated. Ovulatory disorders are often observed due to coexisting endocrinopathy, neoplasms, or emotional states requiring psychological/psychiatric assistance and as a consequence of the use of medications. Therefore, optimally effective research, teaching, and clinical management of ovulatory disorders must be based on a generally accepted and possibly simple classification. Intensive activities that have been recently conducted by international bodies (International Federation of Gynecology and Obstetrics, or FIGO) have resulted in a consensus and the presentation of a proposal for a new classification; according to its authors, this proposal may replace the existing ones, especially the widely used World Health Organization (WHO) classification of ovulatory dysfunction [205,206,207]. Both classifications are summarized in Figure 6.
The WHO classification clearly takes into account the states of hyperprolactinemia in groups V and VI (highlighted on yellow background).
In the FIGO classification, the effect of PRL on ovulation is not directly separated at various levels (hypothalamic, pituitary, or ovarian) of physiological and pathological (PCOS) regulation; in contrast, the WHO classification clearly considers the states of hyperprolactinemia in Groups V and VI.
According to various estimates, polycystic ovary syndrome (PCOS), which is the most common cause of oligoovulation and anovulation (anovulatory infertility), may affect 5 to even 20% of women of reproductive age [208,209,210,211]. In PCOS, abnormal hormone levels prevent ovarian follicles from growing and maturing to ovulation. As a result, immature follicles accumulate in the ovaries, thus resulting in a typical picture of polycystic morphology via ultrasound examination [212]. The pathophysiology of PCOS is heterogeneous and associated with interactions between reproductive function disorders and altered metabolism [213]. Hyperandrogenism and insulin resistance are part of a vicious disease cycle that exacerbates the course of PCOS and is also affected by dysfunction of the hypothalamus-pituitary-ovarian (HPO) axis [214]. Notably, in 30% of PCOS patients, an increase in the serum PRL concentration can be detected in both the follicular and luteal phases of the menstrual cycle [215,216]. It is well documented that hyperprolactinemia may limit the number of growing ovarian follicles and inhibit ovulation [217,218].

3.3.1. PRL and ovulatory disorders

The average basal level of PRL in women is 13 ng/ml (277 mIU/L), whereas the upper normal limit of serum PRL in most laboratories is 15 to 20 ng/ml (320 to 425 mIU/L) [219]. Elevated PRL (hyperprolactinemia) is the most common endocrine disorder of the hypothalamic-pituitary axis. Clinical data clearly indicate an association between hyperprolactinemia and infertility, the main cause of which is ovulatory disorders due to suppression of the HPO axis via inhibition of pulsatile gonadotropin releasing hormone [44].
The vast majority of causes of hyperprolactinemia can be classified as physiological, pathological, or drug-induced (iatrogenic) [42,219,220]. However, despite continuous progress in pathophysiology and diagnostic methods, cases of idiopathic hyperprolactinemia of unknown or no clear cause, as well as hyperprolactinemia, are misdiagnosed due to the use of inadequate analytical techniques [221,222]. Table 3 categorizes the most important causes of hyperprolactinemia and discusses the known or probable underlying mechanisms.
Hypothalamic dopaminergic cells, which are known as tuberoinfundibular dopamine (TIDA) neurons, are located in the arcuate nucleus and send axonal projections to the median eminence. Dopamine is tonically (i.e., continuously) secreted by these dopaminergic neurons to ensure an appropriate level of inhibition of PRL release from pituitary lactotrophs [7]. Therefore, increased PRL secretion under both physiological and pathological conditions mostly results from the removal of dopamine-inhibiting pathways. Hence, most prolactin-relasing factors (PRFs) act indirectly through the disactivation of the TIDA system, although direct effects on lactotrophs and other mechanisms of action (which have not been completely clarified) are certainly present [261,262,263]. Although PRL is well known to stimulate hypothalamic dopamine secretion, thereby exerting negative feedback regulation on its own release, autocrine or paracrine actions of PRL on lactotroph cells have also been suggested [264].
The most common cause of hyperprolactinemia is prolactinoma, which involves a benign (noncancerous) prolactin-releasing tumor, the main prevalence of which is estimated to be approximately 30 per 100,000 people, with a peak incidence occurring at ages 25 to 34 years [265]. Moreover, even in approximately 40% of nonfunctioning pituitary adenomas (NFPAs), benign adenohypophyseal tumors are not associated with clinical evidence of hormonal hypersecretion, and hyperprolactinemia occurs as a result of pituitary lactotroph disinhibition (the stalk effect) [266]. Interestingly, most patients with increased intrasellar pressure caused by large pituitary tumors do not exhibit hyperprolactinemia. Lactotroph insufficiency accompanying pituitary failure may be responsible for 87% of cases of normoprolactinemia among patients with pituitary tumor sizes > 20 mm [267]. Similarly, cases of hypoprolactinemia in the context of ovulatory disorders should be considered accompanying damage to the entire glandular part of the pituitary gland (e.g., in Sheehan syndrome); therefore, it can be combined with gonadotropin deficiencies [268].
As shown in Table 3, a large group of medications can cause an increase in PRL levels, thus impairing dopaminergic activity in the central nervous system (CNS) in various ways, including by acting as a D2 receptor antagonist, a false neurotransmitter, an H2 receptor antagonist, a Ca2+ channel blocker, a selective 5-HT reuptake inhibitor (SSRI) or an inhibitor of the vesicular monoamine transporter type 2 (VMAT2) [269,270]. Latrogenic causes of hyperprolactinemia may be a clinical problem in which the incidence is underestimated, especially in patients who are not taking antipsychotics or antidepressants [103,249,271]. For example, hyperprolactinemia caused by treatment of pregnancy-induced hypertension (PIH) with methyldopa may be associated with an increased incidence of postpartum depression and maternity blues (also known as baby blues) [272].

3.3.1.1. PRL and the release of gonadotropins.

A sufficiently high PRL concentration suppresses hypothalamic gonadotropin-releasing hormone (GnRH, also known as gonadoliberin), which is part of a family of peptides that play pivotal roles in reproduction by stimulating the synthesis and secretion of LH and FSH from the adenohypophysis [81].
When considering the physiological activities of PRL, other than those related to lactation, it can be assumed that a certain level of PRL circulating in the blood, as well as what is produced locally in reproductive tissues, may be necessary for optimal oocyte development, formation and maintenance of the corpus luteum, as well as blastocyst implantation, steroidogenesis in early pregnancy and modulation of the immune system [26,44,273,274,275,276].
However, persistently high levels of PRL can lead to (secondary to GnRH inhibition) hypogonadotropic hypogonadism related to the suppression of both LH and FSH, as well as fertility problems that, in women, are most often a result of ovulation disorders, including the complete disappearance of ovulation [43]. Perhaps surprisingly, only a very small percentage of GnRH neurons express PRLRs or exhibit STAT5 phosphorylation (pSTAT5) in response to an acute PRL stimulus. Moreover, the interaction of PRL with the cell membrane of GnRH neurons is not accompanied by significant modulation of its excitability [277,278]. In addition to changes in PRLR expression under physiological and pathological conditions, the abovementioned findings indicate that PRL does not act directly on GnRH neurons; therefore, the effects of PRL on gonadotropin secretion are mediated by another population of hypothalamic neurons, including those related to Kisspeptin secretion [12,279,280].

3.3.1.2 PRL-kisspeptin interaction

Kisspeptins are a set of peptide fragments encoded in humans by the KISS1 gene [281]. All of these polypeptides have very similar affinities for the kisspeptin receptor KISS-1R (also known as GPR54), which is a G protein-coupled receptor and is considered the canonical receptor for neuropeptides that are products of the KISS1 gene [282,283].
In the mammalian hypothalamus, kisspeptin neurons are mainly located in two areas: the rostral region, which is associated with the preoptic area (POA), and the caudal region, which is associated with the arcuate nucleus (ARC) [282,284]. It has been proposed that neurons in the ARC that coexpress kisspeptin, neurokinin B and dynorphin (KNDy cells) play key roles in GnRH pulse generation, with kisspeptin driving GnRH release and neurokinin B (NKB) and dynorphin acting as start and stop signals, respectively [285,286]. KNDy neurons in the ARC also appear to mediate the negative feedback effects of E2 and are thought to be the main regulators of pulsatile LH secretion. Moreover, KNDy neurons may also be involved in the positive feedback of E2 to induce the LH surge [287]. However, the role of kisspeptin neurons in the POA has not been determined. KNDy neurons within the POA are hypothesized to be involved in the modulatory effects of E2 on thermoregulation [288].
KISS-1R is expressed by GnRH neurons and is directly activated by kisspeptin to stimulate GnRH release [289]. GnRH-secreting neurons form a relatively small population of cells (e.g., approximately 800 neurons in mice and 1,000-2,000 in humans) scattered between the POA and ARC in the shape of an “inverted Y” [290].
Kisspeptin is able to induce GnRH secretion both by stimulating KISS-1R in the neuronal stroma and in GnRH nerve terminals located in the mediobasal hypothalamus (MBH) region [290,291]. By acting directly on GnRH release and directly and/or indirectly on LH and FSH secretion, the kisspeptin/KISS-1R system has been widely reported to be a key factor in the regulation of the hypothalamic-pituitary-gonadal (HPG) axis [146,292]. Loss-of-function mutations in the kisspeptin/KISS-1R system disrupt puberty and infertility in both humans and animal models, whereas mutations that activate this system lead to precocious puberty in humans [293,294,295,296]. Consistently, it has been hypothesized that abnormal kisspeptin signaling may be responsible for stress-induced fertility disorders, including ovulation disorders [145,146,281,297].
Many studies have shown that the significant actions of PRL in modulating the HPG axis are the result of interactions with neurons expressing the KISS1 gene [12,298,299,300]. This is because most KISS1-expressing neurons coexpress functional PRLRs (those receptors through which PRL induces pSTAT5) [301,302]. After acute intraperitoneal (i.p.) administration of PRL to female mice in diestrus, pSTAT induction was observed in approximately 80% of KISS1-expressing neurons in the ARC of the hypothalamus [12,300]. Further confirmation that the PRL/PRL-kisspeptin interaction plays an important role in the regulation of the HPG axis was obtained by demonstrating that systemic or intracerebroventricular (icv) infusion of PRL inhibited KISS1 expression in the hypothalamus, with a subsequent reduction in plasma LH levels [299,303]. Therefore, secondary to the inhibition of GnRH secretion, hypogonadotropic hypogonadism due to hyperprolactinemia is the result of the downregulation of the kisspeptin/KISS-1R signaling system [148,304].
Interestingly, it has been suggested that kisspeptin may have a direct effect on PRL production in lactotrophs of the adenohypophysis under the influence of E2, which may regulate KISS-1R expression and function [305]. KISS-1R appears to be essential for mediating the effect of kisspeptin on PRL secretion, although TIDA neurons do not express KISS-1R and are electrically unresponsive to kisspeptin. It follows that kisspeptin can directly stimulate PRL secretion via KISS-1R in nondopaminergic neurons, whereas the effect on expression of tyrosine hydroxylase TIDA neurons causing an increase in PRL secretion is indirect, which results from inhibition of dopamine release with subsequent pituitary lactotrophs disinhibition. The latter effect doubles the well-documented inhibitory effect of gamma-aminobutyric acid (GABA) within TIDA neurons on dopamine secretion [306]. The kisspeptin-dependent inhibition of dopamine release from TIDA neurons is most likely mediated by the neuropeptide FF receptor 1 (NPFFR1), which is differentially expressed on dopaminergic neurons in the hypothalamus [307]. The occurrence of increased PRL secretion after kisspeptin treatment of TIDA neurons is also dependent on E2 and the expression of estrogen receptor-α (ER-α) on dopaminergic neurons [308].
Therefore, the variability of the functional balance within the PRL-kisspeptin interaction may determine the dominant influence of GnRH or PRL on a given stage of the sexual cycle, including ovulation [12,309,310,311].
The interplay between PRL and kisspeptin in influencing the sexual cycle and ovulation via the HPG axis is shown in Figure 7.

4. Concluding remarks

PRL is a pleiotropic neuroendocrine hormone that is synthesized and secreted mainly by lactotroph cells in the anterior pituitary gland [5,6]. The principal role of PRL in mammals is to regulate lactation [7]. Although the pool of PRL circulating in the blood is almost exclusively of pituitary origin, one should not forget about the extrapituitary sites of PRL synthesis, which may play a role in local regulation. One such location is the ovarian tissue, where depending on the variable expression of PRLRs during the menstrual cycle, PRL (which acts both in an endocrine and paracrine manner) can significantly influence ovulation and the function of the corpus luteum [33,35,36]. However, the nature of these processes corresponding to the physiological state and ovulatory disorders in vivo has still been insufficiently explained, and the results are often contradictory. For example, few studies have reported of a negative relationship between follicular fluid PRL levels and oocyte competence [312,313], whereas other authors have shown that higher follicular PRL levels characterize preovulatory follicles [314] and are also favorable predictors of oocyte maturation and fertilization ability [44,315,316,317]. Notably, the only PRL isoform that has been detected in follicular fluid is the most potent small PRL [318].
When considering the abovementioned effects, it can be assumed that the influence of PRL-dependent granulosa cell apoptosis may constitute a future therapeutic target in the treatment of anovulation and/or corpus luteum dysfunction [202,319]. Moreover, PRL binding activates PRLR, which is a type-1 family cytokine receptor, which then stimulates a signaling cascade through the activation of STAT5. Thus, in patients with hyperprolactinemia, a shift in the immune system balance between proinflammatory and anti-inflammatory factors may manifest itself at the ovarian level as an ovulation disorder (e.g., resulting from abnormal rupture of the wall of the Graafian follicle). In this situation, attempts to influence PRLR expression/signaling via PRLRs in ovarian follicle tissue may prove promising [201,320]. Additionally, regardless of ovulation, the PRL/PRLR axis may play an oncomodulatory role and promote tumor aggressiveness in patients with ovarian cancer [321]. Thus, increased PRLR expression may provide a basis for the development of PRLR antagonists or PRLR-drug conjugates to improve the selective uptake of anticancer drugs [28,321].
Unlike intraovarian mechanisms, the regulatory effect of PRL on the HPG axis in females at the level of the CNS is much better understood.
As previously mentioned, ovulation disorders caused by hypoprolactinemia rarely occur in an isolated form because they are most often the result of damage to the entire glandular part of the pituitary gland, e.g., as a result of puerperal ischemia and necrosis (Sheehan's syndrome). Deficiencies in gonadotropins, such as FSH and LH (but not PRL or GnRH), are responsible for the clinical picture of secondary ovarian failure in these patients [268].
Ovulation disorders involving more or less severe symptoms of hypogonadotropic hypogonadism accompanied by hyperprolactinemia absolutely require diagnostic methods to exclude/confirm prolactinoma and side effects of the utilized drugs (iatrogenic causes) and, subsequently, less common causes of elevated PRL [246,322,323]. Prolactinomas are treated with surgery or DA agonists (e.g., bromocriptine, lisuride, quinagolide, and cabergoline) depending on the adenoma size, clinical factors and patient preference. In microadenomas, patient preference for observation or hormonal replacement therapy (HRT) can also be considered depending on menopausal and gonadal status [324]. It is estimated that treating hyperprolactinemia with DA agonists leads to the normalization of PRL levels and the return of ovulatory cycles in approximately 80% of patients. In treatment-resistant patients, the DA agonist is recommended to be changed [325]. In hyperprolactinemia induced by drugs that cannot be discontinued due to the underlying disease, DA administration may be pointless or even dangerous. Once a pituitary adenoma has been ruled out, the use of sex steroids (HRTs) is recommended in this situation (if necessary) to prevent osteoporosis [325,326].
Kisspeptin also helps to reverse the suppressive effects of hyperprolactinemia on GnRH neurons. It has been demonstrated that the administration of kisspeptin in hyperprolactinemia induces hypothalamic pulsatile GnRH secretion with subsequent pulsatile LH secretion from the adenohypophysis [327]. Clinical algorithms for kisspeptin treatment in ovulation disorders are constantly being developed due to the beneficial effect of this neuropeptide on follicle maturation, as assessed by maturity-related gene expression [328].
Finally, an important consideration in the clinical approach to treating hyperprolactinemia is macroprolactinemia. Macroprolactinemia, which is defined as the quantitative predominance of an isoform of a greater molecular weight than PRL known as macroprolactin (big-big PRL), is a common cause of hyperprolactinemia. According to various data, among patients with hyperprolactinemia, 10-46% were diagnosed with macroprolactinemia [55,56,329]. However, due to the fact that it is usually composed of a PRL monomer and an IgG molecule that has a prolonged clearance rate similar to that of immunoglobulins, macroprolactin is characterized by limited bioavailability (as confined to the vascular system) and much lower bioactivity than PRL. Therefore, the predominance of macroprolactin, which is the main molecular form of PRL in the serum of patients with a normal concentration of monomeric PRL, is associated with no symptoms or a mild course of hyperprolactinemia [52,55,222]. Due to the fact that macroprolactin interferes with many immunological assays that are commonly used for the detection of PRL, macroprolactinemia is a frequent cause of misdiagnosed hyperprolactinemia in clinical practice for the treatment of ovulation disorders [52,330]. Patients with undiagnosed macroprolactinemia may then be unnecessarily exposed to pituitary imaging and to futile treatment with anti-PRL drugs (DA agonists), to which they are resistant. Given the high prevalence of macroprolactinemia among women with elevated PRL levels and the difference in the management of patients with macroprolactinemia compared to true monomeric hyperprolactinemia, all patients with persistently elevated PRL levels, especially asymptomatic patients, should be screened with tests appropriate for the diagnosis of macroprolactinemia [52,331,332]. Due to the fact that the main cause of macroprolactinemia involves anti-PRL antibodies, the diagnosis of a patient with infertility and ovulation disorders should include accompanying autoimmune diseases [333].

Abbreviations

17-OHP 17-hydroxyprogesterone
3β-HSD 3β-hydroxysteroid dehydrogenase
5-HT serotonin (5-hydroxytryptamine)
aa amino acid count
ACTH adrenocorticotropic hormone
AKT protein kinase B
APC antigen-presenting cells
ARC arcuate nucleus (caudal region of the hypothalamus)
BAT brown adipose tissue
BSs, BS1, BS2 binding sites, binding site 1, binding site 2, respectively
Box-1, Box-2 the proline-rich and hydrophobic regions in the intracellular domain of cytokine receptor 1 and 2, respectively
cAMP cyclic adenosine monophosphate
C-C carbon-carbon bond
CNS central nervous system
D1, D2 the two fibronectin type III domains of the prolactin receptor
DA dopamine
DYN dynorphin
E1, E2, E3, E4 estrone, estradiol, estriol and estetrol, respectively
ECR extracellular region of receptor
EPOR erythropoietin receptor
ER-α estrogen receptor-α
ERK1/2 extracellular signal-regulated kinase ½
FAK focal adhesion kinase
FIGO International Federation of Gynecology and Obstetrics
FSH follicle-stimulating hormone
FSHR follicle-stimulating hormone receptor
GABA gamma-aminobutyric acid
GC granulosa cells
GDM gestational diabetes mellitus
GDP, GTP guanosine diphosphate and guanosine triphosphate, respectively
GH growth hormone
GnRH gonadotropin-releasing hormone (gonadoliberin)
GPER G protein-coupled estrogen-receptor
GRB2 growth factor receptor-bound protein 2
hCG human chorionic gonadotropin
HETE hydroxyeicosatetraenoic acid
hGLC human granulosa cells
HPG axis hypothalamic-pituitary-gonadal axis
hPL human placental lactogen (also called human chorionic somatotropin - hCS)
HPO hypothalamic-pituitary-ovarian axis
HRT hormonal replacement therapy
ICR intracellular (cytoplasmic) region of receptor
icv intracerebroventricular
IL-2R interleukin-2 receptor
InhA inhibin A (also marked as αβA)
InhB inhibin B (also marked as αβB)
IRS insulin receptor substrate
JAK2 Janus kinase 2
KISS-1R kisspeptin receptor (also known as GPR54)
KNDγ neurons kisspeptin/neurokinin B/dynorphin neurons
KP kisspeptin
LH luteinizing hormone
LTH lactotrophs (lactotropic cells)
MAOIs monoamine oxidase inhibitors
MAPK mitogen-activated protein kinase
MBH mediobasal region of the hypothalamus
ME median eminence of the hypothalamus
mTOR mammalian target of rapamycin (serine-threonine protein kinase)
NFPAs non-functioning pituitary adenomas
NKB neurokinin B
N-linked NGlyS N-linked glycosylation sites in human proteins
NPFFR1 neuropeptide FF receptor 1
P4 progesterone
PCOS polycystic ovary syndrome
pE pyroglutamate (pyroglutamic acid)
PI3 phosphoinositide 3-kinase
PIH pregnancy-induced hypertension
Pit-1 transcription factor, a member of the POU (Pit-Oct-Unc) homeodomain protein family
POA preoptic area (rostral region of the hypothalamus)
PRFs prolactin-releasing factors
PRL prolactin
PRLBP prolactin binding protein
PRLR prolactin receptor (a member of the class I cytokine receptor family)
PRLR-LF long form of prolactin receptor
pSTAT5 phosphorylated signal transducer and activator of transcription 5
Ras/Raf Ras/Raf kinases
SER smooth endoplasmic reticulum
SHP2 Src homology 2 (SH2) domain
SMARCA3 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A, member 3
SOS son of sevenless, refers to a set of genes encoding guanine nucleotide exchange factors that act on the Ras subfamily of small GTPases
SRC Src family kinases
SSRIs selective serotonin reuptake inhibitors
STAT5 signal transducer and activator of transcription 5
STATs signal transducer and activator of transcription proteins
TCA tricyclic antidepressants
TGF-β transforming growth factor-beta
TIDA neurons tuberoinfundibular dopamine neurons
TMR/TMD transmembrane region/transmembrane domain of receptor
TpoR thrombopoietin receptor (also known as MPL)
TRH thyrotropin-releasing hormone
TSH thyroid-stimulating hormone
VIP vasoactive intestinal peptide
VMAT2 vesicular monoamine transporter type-2
WHO World Health Organization
WSXWS a conserved amino acid sequence (WS motif) in prolactin receptor

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created. Instead, the data are quoted from the available cited literature.

Conflicts of Interest

The author declares no conflict of interest.

References

  1. Stricker P, Grüter F. Action du lobe antérieur de l’hypophyse sur la montée laiteuse. CR Soc Biol. (Paris). 1928, 99, 1978–1980.
  2. Flückiger E, del Pozo E, von Werder K. Prolactin. Physiology, pharmacology and clinical findings. Monographs on Endocrinology 23. Springer, Berlin Heidelberg New York 1982. [CrossRef]
  3. Riddle O, Braucher PF. Control of the special secretion of the crop gland in pigeons by an anterior pituitary hormone. Am J Physiol. 1931, 97, 617–625.
  4. Riddle O, Bates RW, Dykshorn SW. The preparation, identification and assay of prolactin–a hormone of the anterior pituitary. Am J Physiol. 1933, 105, 191–216 http://ajplegacyphysiologyorg/cgi/reprint/105/1/191).
  5. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000, 80, 1523–631. [CrossRef]
  6. Bernard V, Young J, Binart N. Prolactin - a pleiotropic factor in health and disease. Nat Rev Endocrinol. 2019, 15, 356–365. [CrossRef]
  7. Al-Chalabi M, Bass AN, Alsalman I. Physiology, Prolactin. 2022. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507829/. 5078.
  8. Grattan, DR. 60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-prolactin axis. J Endocrinol. 2015, 226, T101–22. [Google Scholar] [CrossRef] [PubMed]
  9. Karayazi Atıcı Ö, Govindrajan N, Lopetegui-González I, Shemanko CS. Prolactin: A hormone with diverse functions from mammary gland development to cancer metastasis. Semin Cell Dev Biol. 2021, 114, 159–170. [CrossRef]
  10. Bachelot A, Binart N. Reproductive role of prolactin. Reproduction. 2007, 133, 361–369. [CrossRef]
  11. Bouilly J, Sonigo C, Auffret J, Gibori G, Binart N. Prolactin signaling mechanisms in ovary. Mol Cell Endocrinol. 2012, 356, 80–7. [CrossRef]
  12. Donato J Jr, Frazão R. Interactions between prolactin and kisspeptin to control reproduction. Arch Endocrinol Metab. 2016, 60, 587–595. [CrossRef]
  13. Basini G, Baioni L, Bussolati S, Grolli S, Grasselli F. Prolactin is a potential physiological modulator of swine ovarian follicle function. Regul Pept. 2014, 189, 22–30. [CrossRef]
  14. Holesh JE, Bass AN, Lord M. Physiology, Ovulation. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.
  15. Laron, Z. The growth hormone-prolactin relationship: a neglected issue. Pediatr Endocrinol Rev. 2011, 9, 546–8. [Google Scholar] [PubMed]
  16. Ben-Jonathan N, Hugo E. Prolactin (PRL) in adipose tissue: regulation and functions. Adv Exp Med Biol. 2015, 846, 1–35. [CrossRef]
  17. Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab. 2007, 9, 464–76. [CrossRef]
  18. Macotela Y, Triebel J, Clapp C. Time for a New Perspective on Prolactin in Metabolism. Trends Endocrinol Metab. 2020, 31, 276–286. [CrossRef]
  19. Pirchio R, Graziadio C, Colao A, Pivonello R, Auriemma RS. Metabolic effects of prolactin. Front Endocrinol (Lausanne). 2022, 13, 1015520. [CrossRef]
  20. Breves JP, Popp EE, Rothenberg EF, Rosenstein CW, Maffett KM, Guertin RR. Osmoregulatory actions of prolactin in the gastrointestinal tract of fishes. Gen Comp Endocrinol. 2020, 298, 113589. [CrossRef]
  21. Foitzik K, Krause K, Conrad F, Nakamura M, Funk W, Paus R. Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine promoter of apoptosis-driven hair follicle regression. Am J Pathol. 2006, 168, 748–56. [CrossRef]
  22. Langan EA, Ramot Y, Hanning A, Poeggeler B, Bíró T, Gaspar E, Funk W, Griffiths CE, Paus R. Thyrotropin-releasing hormone and oestrogen differentially regulate prolactin and prolactin receptor expression in female human skin and hair follicles in vitro. Br J Dermatol. 2010, 162, 1127–31. [CrossRef]
  23. Torner, L. Actions of Prolactin in the Brain: From Physiological Adaptations to Stress and Neurogenesis to Psychopathology. Front Endocrinol (Lausanne). 2016, 7, 25. [Google Scholar] [CrossRef]
  24. Borba VV, Zandman-Goddard G, Shoenfeld Y. Prolactin and Autoimmunity. Front Immunol. 2018, 9, 73. [CrossRef]
  25. Rasmi Y, Jalali L, Khalid S, Shokati A, Tyagi P, Ozturk A, Nasimfar A. The effects of prolactin on the immune system, its relationship with the severity of COVID-19, and its potential immunomodulatory therapeutic effect. Cytokine. 2023, 169, 156253. [CrossRef]
  26. Flores-Espinosa P, Méndez I, Irles C, Olmos-Ortiz A, Helguera-Repetto C, Mancilla-Herrera I, Ortuño-Sahagún D, Goffin V, Zaga-Clavellina V. Immunomodulatory role of decidual prolactin on the human fetal membranes and placenta. Front Immunol. 2023, 14, 1212736. [CrossRef]
  27. Goffin, V. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge. Pharmacol Ther. 2017, 179, 111–126. [Google Scholar] [CrossRef] [PubMed]
  28. Standing D, Dandawate P, Anant S. Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies. Front Endocrinol (Lausanne). 2023, 13, 1112987. [CrossRef]
  29. Ben-Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab. 2002, 13, 245–50. [CrossRef]
  30. Harris J, Stanford PM, Oakes SR, Ormandy CJ. Prolactin and the prolactin receptor: new targets of an old hormone. Ann Med. 2004, 36, 414–25. [CrossRef]
  31. Brooks, CL. Molecular mechanisms of prolactin and its receptor. Endocr Rev. 2012, 33, 504–25. [Google Scholar] [CrossRef]
  32. Gorvin, CM. The prolactin receptor: Diverse and emerging roles in pathophysiology. J Clin Transl Endocrinol. 2015, 2, 85–91. [Google Scholar] [CrossRef]
  33. Marano RJ, Ben-Jonathan N. Minireview: Extrapituitary prolactin: an update on the distribution, regulation, and functions. Mol Endocrinol. 2014, 28, 622–33. [CrossRef]
  34. Featherstone K, White MR, Davis JR. The prolactin gene: a paradigm of tissue-specific gene regulation with complex temporal transcription dynamics. J Neuroendocrinol. 2012, 24, 977–90. [CrossRef]
  35. Perks CM, Newcomb PV, Grohmann M, Wright RJ, Mason HD, Holly JM. Prolactin acts as a potent survival factor against C2-ceramide-induced apoptosis in human granulosa cells. Hum Reprod. 2003, 18, 2672–7. [CrossRef]
  36. Schwärzler P, Untergasser G, Hermann M, Dirnhofer S, Abendstein B, Berger P. Prolactin gene expression and prolactin protein in premenopausal and postmenopausal human ovaries. Fertil Steril. 1997, 68, 696–701. [CrossRef]
  37. Vlahos NP, Bugg EM, Shamblott MJ, Phelps JY, Gearhart JD, Zacur HA. Prolactin receptor gene expression and immunolocalization of the prolactin receptor in human luteinized granulosa cells. Mol Hum Reprod. 2001, 7, 1033–8. [CrossRef]
  38. Porter MB, Brumsted JR, Sites CK. Effect of prolactin on follicle-stimulating hormone receptor binding and progesterone production in cultured porcine granulosa cells. Fertil Steril. 2000, 73, 99–105. [CrossRef]
  39. Ben-Jonathan N, LaPensee CR, LaPensee EW. What can we learn from rodents about prolactin in humans? Endocr Rev. 2008, 29, 1–41. [CrossRef]
  40. Munro MG, Balen AH, Cho S, Critchley HOD, Díaz I, Ferriani R, Henry L, Mocanu E, van der Spuy ZM; FIGO Committee on Menstrual Disorders and Related Health Impacts, and FIGO Committee on Reproductive Medicine, Endocrinology, and Infertility. The FIGO Ovulatory Disorders Classification System. Hum Reprod. 2022, 37, 2446–2464. [CrossRef]
  41. Vander Borght M, Wyns C. Fertility and infertility: Definition and epidemiology. Clin Biochem. 2018, 62, 2–10. [CrossRef]
  42. Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. 2013, 6, 168–75. [CrossRef]
  43. Štelcl M, Vrublovský P, Machač Š. Prolactin and alteration of fertility. Ceska Gynekol. 2018, 83, 232–235.
  44. Iancu ME, Albu AI, Albu DN. Prolactin Relationship with Fertility and In Vitro Fertilization Outcomes-A Review of the Literature. Pharmaceuticals (Basel). 2023, 16, 122. [CrossRef]
  45. Keeler C, Dannies PS, Hodsdon ME. The tertiary structure and backbone dynamics of human prolactin. J Mol Biol. 2003, 328, 1105–21. [CrossRef]
  46. Sinha, YN. Structural variants of prolactin: occurrence and physiological significance. Endocr Rev. 1995, 16, 354–69. [Google Scholar] [CrossRef] [PubMed]
  47. Horseman ND, Yu-Lee LY. Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin, and hematopoietic cytokines. Endocr Rev. 1994, 15, 627–49. [CrossRef]
  48. Corbacho AM, Martínez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol. 2002, 173, 219–38. [CrossRef]
  49. Owerbach D, Rutter WJ, Cooke NE, Martial JA, Shows TB. The prolactin gene is located on chromosome 6 in humans. Science. 1981, 212, 815–6. [CrossRef]
  50. McNamara AV, Awais R, Momiji H, Dunham L, Featherstone K, Harper CV, Adamson AA, Semprini S, Jones NA, Spiller DG, Mullins JJ, Finkenstädt BF, Rand D, White MRH, Davis JRE. Transcription Factor Pit-1 Affects Transcriptional Timing in the Dual-Promoter Human Prolactin Gene. Endocrinology. 2021, 162, bqaa249. [CrossRef]
  51. Trott JF, Hovey RC, Koduri S, Vonderhaar BK. Alternative splicing to exon 11 of human prolactin receptor gene results in multiple isoforms including a secreted prolactin-binding protein. J Mol Endocrinol. 2003, 30, 31–47. [CrossRef]
  52. Kasum M, Orešković S, Čehić E, Šunj M, Lila A, Ejubović E. Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia. Taiwan J Obstet Gynecol. 2017, 56, 719–724. [CrossRef]
  53. Vilar L, Vilar CF, Lyra R, Freitas MDC. Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia. Neuroendocrinology. 2019, 109, 7–19. [CrossRef]
  54. Thirunavakkarasu K, Dutta P, Sridhar S, Dhaliwal L, Prashad GR, Gainder S, Sachdeva N, Bhansali A. Macroprolactinemia in hyperprolactinemic infertile women. Endocrine. 2013, 44, 750–5. [CrossRef]
  55. Koniares K, Benadiva C, Engmann L, Nulsen J, Grow D. Macroprolactinemia: a mini-review and update on clinical practice. F S Rep. 2023, 4, 245–250. [CrossRef]
  56. Kasum M, Pavičić-Baldani D, Stanić P, Orešković S, Sarić JM, Blajić J, Juras J. Importance of macroprolactinemia in hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol. 2014, 183, 28–32. [CrossRef]
  57. Bugge K, Papaleo E, Haxholm GW, Hopper JT, Robinson CV, Olsen JG, Lindorff-Larsen K, Kragelund BB. A combined computational and structural model of the full-length human prolactin receptor. Nat Commun. 2016, 7, 11578. [CrossRef]
  58. Araya-Secchi R, Bugge K, Seiffert P, Petry A, Haxholm GW, Lindorff-Larsen K, Pedersen SF, Arleth L, Kragelund BB. The prolactin receptor scaffolds Janus kinase 2 via co-structure formation with phosphoinositide-4,5-bisphosphate. Elife. 2023, 12, e84645. [CrossRef]
  59. Lee SA, Haiman CA, Burtt NP, Pooler LC, Cheng I, Kolonel LN, Pike MC, Altshuler D, Hirschhorn JN, Henderson BE, Stram DO. A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort. BMC Med Genet. 2007, 8, 72. [CrossRef]
  60. Gorvin CM, Newey PJ, Thakker RV. Identification of prolactin receptor variants with diverse effects on receptor signalling. J Mol Endocrinol. 2023, 70, e220164. [CrossRef]
  61. Dagil R, Knudsen MJ, Olsen JG, O'Shea C, Franzmann M, Goffin V, Teilum K, Breinholt J, Kragelund BB. The WSXWS motif in cytokine receptors is a molecular switch involved in receptor activation: insight from structures of the prolactin receptor. Structure. 2012, 20, 270–82. [CrossRef]
  62. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998, 19, 225–68. [CrossRef]
  63. Fresno Vara JA, Carretero MV, Gerónimo H, Ballmer-Hofer K, Martín-Pérez J. Stimulation of c-Src by prolactin is independent of Jak2. Biochem J. 2000, 345 Pt 1(Pt 1), 17-24. [CrossRef]
  64. Kavarthapu R, Dufau ML.. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness. Front Endocrinol (Lausanne). 2022, 13, 949396. [CrossRef]
  65. Haxholm GW, Nikolajsen LF, Olsen JG, Fredsted J, Larsen FH, Goffin V, Pedersen SF, Brooks AJ, Waters MJ, Kragelund BB. Intrinsically disordered cytoplasmic domains of two cytokine receptors mediate conserved interactions with membranes. Biochem J. 2015, 468, 495–506. [CrossRef]
  66. Hu ZZ, Meng J, Dufau ML.. Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11. J Biol Chem. 2001, 276, 41086–94. [CrossRef]
  67. Tsai-Morris CH, Dufau ML. PRLR (prolactin receptor). In: Atlas Genet Cytogenet Oncol Haematol (2011). Available at: http://atlasgeneticsoncology.org/gene/42891/.
  68. Abramicheva PA, Smirnova OV. Prolactin Receptor Isoforms as the Basis of Tissue-Specific Action of Prolactin in the Norm and Pathology. Biochemistry (Mosc). 2019, 84, 329–345. [CrossRef]
  69. Berthon P, Kelly PA, Djiane J. Water-soluble prolactin receptors from porcine mammary gland. Proc Soc Exp Biol Med. 1987, 184, 300–6. [CrossRef]
  70. Postel-Vinay MC, Belair L, Kayser C, Kelly PA, Djiane J. Identification of prolactin and growth hormone binding proteins in rabbit milk. Proc Natl Acad Sci U S A. 1991, 88, 6687–90. [CrossRef]
  71. Ezoe K, Miki T, Ohata K, Fujiwara N, Yabuuchi A, Kobayashi T, Kato K. Prolactin receptor expression and its role in trophoblast outgrowth in human embryos. Reprod Biomed Online. 2021, 42, 699–707. [CrossRef]
  72. Utama FE, Tran TH, Ryder A, LeBaron MJ, Parlow AF, Rui H. Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells. Endocrinology. 2009, 150, 1782–90. [CrossRef]
  73. Pezet A, Buteau H, Kelly PA, Edery M. The last proline of Box 1 is essential for association with JAK2 and functional activation of the prolactin receptor. Mol Cell Endocrinol. 1997, 129, 199–208. [CrossRef]
  74. Brockman JL, Schuler LA. Prolactin signals via Stat5 and Oct-1 to the proximal cyclin D1 promoter. Mol Cell Endocrinol. 2005, 239(1-2):45-53. [CrossRef]
  75. Aksamitiene E, Achanta S, Kolch W, Kholodenko BN, Hoek JB, Kiyatkin A. Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells. Cell Signal. 2011, 23, 1794–805. [CrossRef]
  76. Derwich A, Sykutera M, Bromińska B, Rubiś B, Ruchała M, Sawicka-Gutaj N. The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review. Int J Mol Sci. 2023, 24, 10952. [CrossRef]
  77. Bishop JD, Nien WL, Dauphinee SM, Too CK. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells. J Endocrinol. 2006, 190, 307–12. [CrossRef]
  78. Hewetson A, Moore SL, Chilton BS. Prolactin signals through RUSH/SMARCA3 in the absence of a physical association with Stat5a. Biol Reprod. 2004, 71, 1907–12. [CrossRef]
  79. Hannan FM, Elajnaf T, Vandenberg LN, Kennedy SH, Thakker RV. Hormonal regulation of mammary gland development and lactation. Nat Rev Endocrinol. 2023, 19, 46–61. [CrossRef]
  80. Auriemma RS, Del Vecchio G, Scairati R, Pirchio R, Liccardi A, Verde N, de Angelis C, Menafra D, Pivonello C, Conforti A, Alviggi C, Pivonello R, Colao A. The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology. Front Endocrinol (Lausanne). 2020, 11, 594370. [CrossRef]
  81. Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R. Approach to the Patient With Prolactinoma. J Clin Endocrinol Metab. 2023, 108, 2400–2423. [CrossRef]
  82. Moriwaki M, Welt CK. PRL Mutation Causing Alactogenesis: Insights Into Prolactin Structure and Function Relationships. J Clin Endocrinol Metab. 2021, 106, e3021–e3026. [CrossRef]
  83. Naylor MJ, Lockefeer JA, Horseman ND, Ormandy CJ. Prolactin regulates mammary epithelial cell proliferation via autocrine/paracrine mechanism. Endocrine. 2003, 20(1-2), 111-4. [CrossRef]
  84. Gabrielson M, Ubhayasekera K, Ek B, Andersson Franko M, Eriksson M, Czene K, Bergquist J, Hall P. Inclusion of Plasma Prolactin Levels in Current Risk Prediction Models of Premenopausal and Postmenopausal Breast Cancer. JNCI Cancer Spectr. 2018 Dec 4;2, pky055. [CrossRef]
  85. Sackmann-Sala L, Guidotti JE, Goffin V. Minireview: prolactin regulation of adult stem cells. Mol Endocrinol. 2015, 29, 667–81. [CrossRef]
  86. Vázquez-Membrillo M, Siqueiros-Márquez L, Núñez FF, Díaz-Lezama N, Adán-Castro E, Ramírez-Hernández G, Adán N, Macotela Y, Martínez de la Escalera G, Clapp C. Prolactin stimulates the vascularisation of the retina in newborn mice under hyperoxia conditions. J Neuroendocrinol. 2020, 32, e12858. [CrossRef]
  87. Yousefvand S, Hadjzadeh MA, Vafaee F, Dolatshad H. The protective effects of prolactin on brain injury. Life Sci. 2020, 263, 118547. [CrossRef]
  88. Molina-Salinas G, Rivero-Segura NA, Cabrera-Reyes EA, Rodríguez-Chávez V, Langley E, Cerbon M. Decoding signaling pathways involved in prolactin-induced neuroprotection: A review. Front Neuroendocrinol. 2021, 61, 100913. [CrossRef]
  89. Rodriguez-Chavez V, Moran J, Molina-Salinas G, Zepeda Ruiz WA, Rodriguez MC, Picazo O, Cerbon M. Participation of Glutamatergic Ionotropic Receptors in Excitotoxicity: The Neuroprotective Role of Prolactin. Neuroscience. 2021, 461:180-193. [CrossRef]
  90. Clevenger CV, Rui H. Breast Cancer and Prolactin - New Mechanisms and Models. Endocrinology. 2022, 163, bqac122. [CrossRef]
  91. Ramírez-de-Arellano A, Villegas-Pineda JC, Hernández-Silva CD, Pereira-Suárez AL. The Relevant Participation of Prolactin in the Genesis and Progression of Gynecological Cancers. Front Endocrinol (Lausanne). 2021, 12:747810. [CrossRef]
  92. Baeyens L, Hindi S, Sorenson RL, German MS. β-Cell adaptation in pregnancy. Diabetes Obes Metab. 2016, 18 Suppl 1(Suppl 1):63-70. [CrossRef]
  93. Al-Nami MS, Al-Kuraishy HM, Al-Gareeb AI, Al-Mamoori F. Metabolic profile and prolactin serum levels in men with type 2 diabetes mellitus: Old-new rubric. Int J Crit Illn Inj Sci. 2019, 9, 120–126. [CrossRef]
  94. Zhu C, Wen X, You H, Lu L, Du L, Qian C. Improved Insulin Secretion Response and Beta-cell Function Correlated with Increased Prolactin Levels After Laparoscopic Sleeve Gastrectomy in Morbidly Obese Patients with Acanthosis Nigricans. Obes Surg. 2023, 33, 2405–2419. [CrossRef]
  95. Retnakaran R, Ye C, Kramer CK, Connelly PW, Hanley AJ, Sermer M, Zinman B. Maternal Serum Prolactin and Prediction of Postpartum β-Cell Function and Risk of Prediabetes/Diabetes. Diabetes Care. 2016, 39, 1250–8. [CrossRef]
  96. Rassie K, Giri R, Joham AE, Mousa A, Teede H. Prolactin in relation to gestational diabetes and metabolic risk in pregnancy and postpartum: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022, 13:1069625. [CrossRef]
  97. Wang T, Lu J, Xu Y, Li M, Sun J, Zhang J, Xu B, Xu M, Chen Y, Bi Y, Wang W, Ning G. Circulating prolactin associates with diabetes and impaired glucose regulation: a population-based study. Diabetes Care. 2013, 36, 1974–80. [CrossRef]
  98. Yang H, Lin J, Li H, Liu Z, Chen X, Chen Q. Prolactin Is Associated With Insulin Resistance and Beta-Cell Dysfunction in Infertile Women With Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2021, 12:571229. [CrossRef]
  99. Rasheed HA, Al-Kuraishy HM, Al-Gareeb AI, Hussien NR, Al-Nami MS. Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: Bane or Boon. J Adv Pharm Technol Res. 2019, 10, 163–168. [CrossRef]
  100. Shao S, Yao Z, Lu J, Song Y, He Z, Yu C, Zhou X, Zhao L, Zhao J, Gao L.. Ablation of prolactin receptor increases hepatic triglyceride accumulation. Biochem Biophys Res Commun. 2018, 498, 693–699. [CrossRef]
  101. de Winne C, Pascual FL, Lopez-Vicchi F, Etcheverry-Boneo L, Mendez-Garcia LF, Ornstein AM, Lacau-Mengido IM, Sorianello E, Becu-Villalobos D. Neuroendocrine control of brown adipocyte function by prolactin and growth hormone. J Neuroendocrinol. 2023:e13248. [CrossRef]
  102. Ghoreshi ZA, Akbari H, Sharif-Zak M, Arefinia N, Abbasi-Jorjandi M, Asadikaram G. Recent findings on hyperprolactinemia and its pathological implications: a literature review. J Investig Med. 2022, 70, 1443–1451. [CrossRef]
  103. Corona G, Rastrelli G, Comeglio P, Guaraldi F, Mazzatenta D, Sforza A, Vignozzi L, Maggi M. The metabolic role of prolactin: systematic review, meta-analysis and preclinical considerations. Expert Rev Endocrinol Metab. 2022, 17, 533–545. [CrossRef]
  104. Xu P, Zhu Y, Ji X, Ma H, Zhang P, Bi Y. Lower serum PRL is associated with the development of non-alcoholic fatty liver disease: a retrospective cohort study. BMC Gastroenterol. 2022, 22, 523. [CrossRef]
  105. Deachapunya C, Poonyachoti S, Krishnamra N. Regulation of electrolyte transport across cultured endometrial epithelial cells by prolactin. J Endocrinol. 2008, 197, 575–82. [CrossRef]
  106. Radojkovic D, Pesic M, Radojkovic M, Dimic D, Vukelic Nikolic M, Jevtovic Stoimenov T, Radenkovic S, Velojic Golubovic M, Radjenovic Petkovic T, Antic S. Expression of prolactin receptors in the duodenum, kidneys and skeletal system during physiological and sulpiride-induced hyperprolactinaemia. Endocrine. 2018, 62, 681–691. [CrossRef]
  107. Ibarra F, Crambert S, Eklöf AC, Lundquist A, Hansell P, Holtbäck U. Prolactin, a natriuretic hormone, interacting with the renal dopamine system. Kidney Int. 2005, 68, 1700–7. [CrossRef]
  108. Crambert S, Sjöberg A, Eklöf AC, Ibarra F, Holtbäck U. Prolactin and dopamine 1-like receptor interaction in renal proximal tubular cells. Am J Physiol Renal Physiol. 2010, 299, F49–54. [CrossRef]
  109. Georgescu T, Swart JM, Grattan DR, Brown RSE. The Prolactin Family of Hormones as Regulators of Maternal Mood and Behavior. Front Glob Womens Health. 2021, 2:767467. [CrossRef]
  110. Faron-Górecka A, Latocha K, Pabian P, Kolasa M, Sobczyk-Krupiarz I, Dziedzicka-Wasylewska M. The Involvement of Prolactin in Stress-Related Disorders. Int J Environ Res Public Health. 2023, 20, 3257. [CrossRef]
  111. Reavley A, Fisher AD, Owen D, Creed FH, Davis JR. Psychological distress in patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 1997, 47, 343–8. [CrossRef]
  112. Elgellaie A, Larkin T, Kaelle J, Mills J, Thomas S. Plasma prolactin is higher in major depressive disorder and females, and associated with anxiety, hostility, somatization, psychotic symptoms and heart rate. Compr Psychoneuroendocrinol. 2021, 6:100049. [CrossRef]
  113. Telfer EE, Grosbois J, Odey YL, Rosario R, Anderson RA. Making a good egg: human oocyte health, aging, and in vitro development. Physiol Rev. 2023, 103, 2623–2677. [CrossRef]
  114. Marques P, Skorupskaite K, Rozario KS, et al. Physiology of GnRH and Gonadotropin Secretion. [Updated 2022 Jan 5]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279070/.
  115. Marshall JC, Dalkin AC, Haisenleder DJ, Paul SJ, Ortolano GA, Kelch RP. Gonadotropin-releasing hormone pulses: regulators of gonadotropin synthesis and ovulatory cycles. Recent Prog Horm Res. 1991, 47:155-87; discussion 188-9. [CrossRef]
  116. Orlowski M, Sarao MS. Physiology, Follicle Stimulating Hormone. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535442/. 1 May.
  117. Reed BG, Carr BR. The Normal Menstrual Cycle and the Control of Ovulation. [Updated 2018 Aug 5]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279054/.
  118. Nedresky D, Singh G. Physiology, Luteinizing Hormone. [Updated 2022 Sep 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539692/.
  119. Cable JK, Grider MH. Physiology, Progesterone. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558960/. 1 May.
  120. Findlay JK, Drummond AE, Dyson M, Baillie AJ, Robertson DM, Ethier JF. Production and actions of inhibin and activin during folliculogenesis in the rat. Mol Cell Endocrinol. 2001, 180(1-2):139-44. [CrossRef]
  121. Namwanje M, Brown CW. Activins and Inhibins: Roles in Development, Physiology, and Disease. Cold Spring Harb Perspect Biol. 2016, 8, a021881. [CrossRef]
  122. Roseff SJ, Bangah ML, Kettel LM, Vale W, Rivier J, Burger HG, Yen SS. Dynamic changes in circulating inhibin levels during the luteal-follicular transition of the human menstrual cycle. J Clin Endocrinol Metab. 1989, 69, 1033–9. [CrossRef]
  123. Welt CK, Schneyer AL.. Differential regulation of inhibin B and inhibin a by follicle-stimulating hormone and local growth factors in human granulosa cells from small antral follicles. J Clin Endocrinol Metab. 2001, 86, 330–6. [CrossRef]
  124. Scaramuzzi RJ, Baird DT, Campbell BK, Driancourt MA, Dupont J, Fortune JE, Gilchrist RB, Martin GB, McNatty KP, McNeilly AS, Monget P, Monniaux D, Viñoles C, Webb R. Regulation of folliculogenesis and the determination of ovulation rate in ruminants. Reprod Fertil Dev. 2011, 23, 444–67. [CrossRef]
  125. Lundy T, Smith P, O'Connell A, Hudson NL, McNatty KP. Populations of granulosa cells in small follicles of the sheep ovary. J Reprod Fertil. 1999 ;115, 251-62. [CrossRef]
  126. Dunlop CE, Anderson RA. The regulation and assessment of follicular growth. Scand J Clin Lab Invest Suppl. 2014, 244:13-7; discussion 17. [CrossRef]
  127. Gershon E, Dekel N. Newly Identified Regulators of Ovarian Folliculogenesis and Ovulation. Int J Mol Sci. 2020, 21, 4565. [CrossRef]
  128. Evans AC, Fortune JE. Selection of the dominant follicle in cattle occurs in the absence of differences in the expression of messenger ribonucleic acid for gonadotropin receptors. Endocrinology. 1997, 138, 2963–71. [CrossRef]
  129. de Andrade LG, Portela VM, Dos Santos EC, Aires KV, Ferreira R, Missio D, da Silva Z, Koch J, Antoniazzi AQ, Gonçalves PBD, Zamberlam G. FSH Regulates YAP-TEAD Transcriptional Activity in Bovine Granulosa Cells to Allow the Future Dominant Follicle to Exert Its Augmented Estrogenic Capacity. Int J Mol Sci. 2022, 23, 14160. [CrossRef]
  130. Casarini L, Paradiso E, Lazzaretti C, D'Alessandro S, Roy N, Mascolo E, Zaręba K, García-Gasca A, Simoni M. Regulation of antral follicular growth by an interplay between gonadotropins and their receptors. J Assist Reprod Genet. 2022, 39, 893–904. [CrossRef]
  131. Rosen MP, Zamah AM, Shen S, Dobson AT, McCulloch CE, Rinaudo PF, Lamb JD, Cedars MI. The effect of follicular fluid hormones on oocyte recovery after ovarian stimulation: FSH level predicts oocyte recovery. Reprod Biol Endocrinol. 2009, 7:35. [CrossRef]
  132. Chauvin S, Cohen-Tannoudji J, Guigon CJ. Estradiol Signaling at the Heart of Folliculogenesis: Its Potential Deregulation in Human Ovarian Pathologies. Int J Mol Sci. 2022, 23, 512. [CrossRef]
  133. Stringer JM, Alesi LR, Winship AL, Hutt KJ. Beyond apoptosis: evidence of other regulated cell death pathways in the ovary throughout development and life. Hum Reprod Update. 2023, 29, 434–456. [CrossRef]
  134. Shelling AN, Ahmed Nasef N. The Role of Lifestyle and Dietary Factors in the Development of Premature Ovarian Insufficiency. Antioxidants (Basel). 2023, 12, 1601. [CrossRef]
  135. Sun YC, Wang YY, Sun XF, Cheng SF, Li L, Zhao Y, Shen W, Chen H. The role of autophagy during murine primordial follicle assembly. Aging (Albany NY). 2018, 10, 197–211. [CrossRef]
  136. Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA. Genetic markers of ovarian follicle number and menopause in women of multiple ethnicities. Hum Genet. 2012, 131, 1709–24. [CrossRef]
  137. Irving-Rodgers HF, van Wezel IL, Mussard ML, Kinder JE, Rodgers RJ. Atresia revisited: two basic patterns of atresia of bovine antral follicles. Reproduction. 2001, 122, 761–75.
  138. Zhou J, Peng X, Mei S. Autophagy in Ovarian Follicular Development and Atresia. Int J Biol Sci. 2019, 15, 726–737. [CrossRef]
  139. Li L, Shi X, Shi Y, Wang Z. The Signaling Pathways Involved in Ovarian Follicle Development. Front Physiol. 2021, 12:730196. [CrossRef]
  140. Gellersen B, Brosens JJ. Cyclic decidualization of the human endometrium in reproductive health and failure. Endocr Rev. 2014, 35, 851–905. [CrossRef]
  141. Baerwald A, Pierson R. Ovarian follicular waves during the menstrual cycle: physiologic insights into novel approaches for ovarian stimulation. Fertil Steril. 2020, 114, 443–457. [CrossRef]
  142. Bulletti C, Bulletti FM, Sciorio R, Guido M. Progesterone: The Key Factor of the Beginning of Life. Int J Mol Sci. 2022, 23, 14138. [CrossRef]
  143. Klusmann H, Schulze L, Engel S, Bücklein E, Daehn D, Lozza-Fiacco S, Geiling A, Meyer C, Andersen E, Knaevelsrud C, Schumacher S. HPA axis activity across the menstrual cycle - a systematic review and meta-analysis of longitudinal studies. Front Neuroendocrinol. 2022, 66: 100998. [CrossRef]
  144. Javed Z, Qamar U, Sathyapalan T. The role of kisspeptin signalling in the hypothalamic-pituitary-gonadal axis--current perspective. Endokrynol Pol. 2015, 66, 534–47. [CrossRef]
  145. 145 Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014, 20, 485–500. [CrossRef]
  146. Stevenson H, Bartram S, Charalambides MM, Murthy S, Petitt T, Pradeep A, Vineall O, Abaraonye I, Lancaster A, Koysombat K, Patel B, Abbara A. Kisspeptin-neuron control of LH pulsatility and ovulation. Front Endocrinol (Lausanne). 2022, 13:951938. [CrossRef]
  147. Kauffman, AS. Neuroendocrine mechanisms underlying estrogen positive feedback and the LH surge. Front Neurosci. 2022, 16:953252. [CrossRef]
  148. Tsukamura, H. Kobayashi Award 2019: The neuroendocrine regulation of the mammalian reproduction. Gen Comp Endocrinol. 2022, 315:113755. [CrossRef]
  149. Welt, CK. Regulation and function of inhibins in the normal menstrual cycle. Semin Reprod Med. 2004, 22, 187–93. [Google Scholar] [CrossRef]
  150. Namwanje M, Brown CW. Activins and Inhibins: Roles in Development, Physiology, and Disease. Cold Spring Harb Perspect Biol. 2016, 8, a021881. [CrossRef]
  151. Perakakis N, Upadhyay J, Ghaly W, Chen J, Chrysafi P, Anastasilakis AD, Mantzoros CS. Regulation of the activins-follistatins-inhibins axis by energy status: Impact on reproductive function. Metabolism. 2018, 85:240-249. [CrossRef]
  152. Tumurgan Z, Kanasaki H, Tumurbaatar T, Oride A, Okada H, Hara T, Kyo S. Role of activin, follistatin, and inhibin in the regulation of Kiss-1 gene expression in hypothalamic cell models. Biol Reprod. 2019, 101, 405–415. [CrossRef]
  153. Oxford Handbook of Clinical and Laboratory Investigation. Editor: Drew Provan; 4th edition (2018); Oxford University Press New York, USA.
  154. Sikaris, KA. Enhancing the Clinical Value of Medical Laboratory Testing. Clin Biochem Rev. 2017, 38, 107–114. [Google Scholar] [PubMed]
  155. Sperduti S, Limoncella S, Lazzaretti C, Paradiso E, Riccetti L, Turchi S, Ferrigno I, Bertacchini J, Palumbo C, Potì F, Longobardi S, Millar RP, Simoni M, Newton CL, Casarini L.. GnRH Antagonists Produce Differential Modulation of the Signaling Pathways Mediated by GnRH Receptors. Int J Mol Sci. 2019, 20, 5548. [CrossRef]
  156. Choi, D. Evolutionary Viewpoint on GnRH (gonadotropin-releasing hormone) in Chordata - Amino Acid and Nucleic Acid Sequences. Dev Reprod. 2018, 22, 119–132. [Google Scholar] [CrossRef] [PubMed]
  157. Ferris HA, Shupnik MA. Mechanisms for pulsatile regulation of the gonadotropin subunit genes by GNRHBiol Reprod. 2006, 74, 993–8. [CrossRef]
  158. Nippoldt TB, Reame NE, Kelch RP, Marshall JC. The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the menstrual cycle. J Clin Endocrinol Metab. 1989, 69, 67–76. [CrossRef]
  159. Romano GJ, Krust A, Pfaff DW. Expression and estrogen regulation of progesterone receptor mRNA in neurons of the mediobasal hypothalamus: an in situ hybridization study. Mol Endocrinol. 1989, 3, 1295–300, Erratum in: Mol Endocrinol 1989, 3, 1860. [CrossRef]
  160. Soules MR, Steiner RA, Clifton DK, Cohen NL, Aksel S, Bremner WJ. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab. 1984, 58, 378–83. [CrossRef]
  161. Berga SL, Yen SS. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1989, 30, 177–84. [CrossRef]
  162. Neal-Perry G, Lebesgue D, Lederman M, Shu J, Zeevalk GD, Etgen AM. The excitatory peptide kisspeptin restores the luteinizing hormone surge and modulates amino acid neurotransmission in the medial preoptic area of middle-aged rats. Endocrinology. 2009, 150, 3699–708. [CrossRef]
  163. Araki S, Takanashi N, Chikazawa K, Motoyama M, Akabori A, Konuma S, Tamada T. Reevaluation of immunoreactive gonadotropin-releasing hormone (GnRH) levels in general circulation in women: changes in levels and episodic patterns before, during and after gonadotropin surges. Endocrinol Jpn. 1986, 33, 457–68. [CrossRef]
  164. Andersen CY, Ezcurra D. Human steroidogenesis: implications for controlled ovarian stimulation with exogenous gonadotropins. Reprod Biol Endocrinol. 2014, 12:128. [CrossRef]
  165. Dias JA, Ulloa-Aguirre A. New Human Follitropin Preparations: How Glycan Structural Differences May Affect Biochemical and Biological Function and Clinical Effect. Front Endocrinol (Lausanne). 2021, 12:636038. [CrossRef]
  166. Bousfield GR, Butnev VY, White WK, Hall AS, Harvey DJ. Comparison of Follicle-Stimulating Hormone Glycosylation Microheterogenity by Quantitative Negative Mode Nano-Electrospray Mass Spectrometry of Peptide-N Glycanase-Released Oligosaccharides. J Glycomics Lipidomics. 2015, 5, 129. [CrossRef]
  167. Fink, G., Gonadotropin secretion and its control, in The physiology of reproduction, E. Knobil, J.D. Neill, and et al., Editors. 1988, Raven: New York. p. 1349-1377.
  168. Oduwole OO, Huhtaniemi IT, Misrahi M. The Roles of Luteinizing Hormone, Follicle-Stimulating Hormone and Testosterone in Spermatogenesis and Folliculogenesis Revisited. Int J Mol Sci. 2021, 22, 12735. [CrossRef]
  169. Amsterdam A, Rotmensch S. Structure-function relationships during granulosa cell differentiation. Endocr Rev. 1987, 8, 309–37. [CrossRef]
  170. Larson SB, McPherson A. The crystal structure of the β subunit of luteinizing hormone and a model for the intact hormone. Curr Res Struct Biol. 2019, 1:1-5. [CrossRef]
  171. Filicori, M. The role of luteinizing hormone in folliculogenesis and ovulation induction. Fertil Steril. 1999, 71, 405–14. [Google Scholar] [CrossRef]
  172. Kumar P, Sait SF. Luteinizing hormone and its dilemma in ovulation induction. J Hum Reprod Sci. 2011, 4, 2–7. [CrossRef]
  173. Duffy DM, Ko C, Jo M, Brannstrom M, Curry TE. Ovulation: Parallels With Inflammatory Processes. Endocr Rev. 2019, 40, 369–416. [CrossRef]
  174. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Replacement Therapy; Jackson LM, Parker RM, Mattison DR, editors. The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use. Washington (DC): National Academies Press (US); 2020 Jul 1. 4, Reproductive Steroid Hormones: Synthesis, Structure, and Biochemistry. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562873/.
  175. Xu XL, Huang ZY, Yu K, Li J, Fu XW, Deng SL. Estrogen Biosynthesis and Signal Transduction in Ovarian Disease. Front Endocrinol (Lausanne). 2022, 13:827032. [CrossRef]
  176. Daniel JM, Lindsey SH, Mostany R, Schrader LA, Zsombok A. Cardiometabolic health, menopausal estrogen therapy and the brain: How effects of estrogens diverge in healthy and unhealthy preclinical models of aging. Front Neuroendocrinol. 2023, 70:101068. [CrossRef]
  177. Chakraborty B, Byemerwa J, Krebs T, Lim F, Chang CY, McDonnell DP. Estrogen Receptor Signaling in the Immune System. Endocr Rev. 2023, 44, 117–141. [CrossRef]
  178. Kim HJJ, Dickie SA, Laprairie RB. Estradiol-dependent hypocretinergic/orexinergic behaviors throughout the estrous cycle. Psychopharmacology (Berl). 2023, 240, 15–25. [CrossRef]
  179. Bühler M, Stolz A. Estrogens-Origin of Centrosome Defects in Human Cancer? Cells. 2022, 11, 432. [CrossRef]
  180. Hamilton KJ, Arao Y, Korach KS. Estrogen hormone physiology: reproductive findings from estrogen receptor mutant mice. Reprod Biol. 2014, 14, 3–8. [CrossRef]
  181. Christenson LK, Devoto L. Cholesterol transport and steroidogenesis by the corpus luteum. Reprod Biol Endocrinol. 2003, 1:90. [CrossRef]
  182. Ng SW, Norwitz GA, Pavlicev M, Tilburgs T, Simón C, Norwitz ER. Endometrial Decidualization: The Primary Driver of Pregnancy Health. Int J Mol Sci. 2020, 21, 4092. [CrossRef]
  183. Tuckey, RC. Progesterone synthesis by the human placenta. Placenta. 2005, 26, 273–81. [Google Scholar] [CrossRef] [PubMed]
  184. Robertson DM, Cahir N, Findlay JK, Burger HG, Groome N. The biological and immunological characterization of inhibin A and B forms in human follicular fluid and plasma. J Clin Endocrinol Metab. 1997, 82, 889–96. [CrossRef]
  185. Walton KL, Makanji Y, Wilce MC, Chan KL, Robertson DM, Harrison CA. A common biosynthetic pathway governs the dimerization and secretion of inhibin and related transforming growth factor beta (TGFbeta) ligands. J Biol Chem. 2009, 284, 9311–20. [CrossRef]
  186. Yu J, Shao LE, Lemas V, Yu AL, Vaughan J, Rivier J, Vale W. Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature. 1987, 330, 765–7. [CrossRef]
  187. Vassalli A, Matzuk MM, Gardner HA, Lee KF, Jaenisch R. Activin/inhibin beta B subunit gene disruption leads to defects in eyelid development and female reproduction. Genes Dev. 1994, 8, 414–27. [CrossRef]
  188. Matzuk, MM. Functional analysis of mammalian members of the transforming growth factor-beta superfamily. Trends Endocrinol Metab. 1995, 6, 120–7. [Google Scholar] [CrossRef]
  189. Morikawa M, Derynck R, Miyazono K. TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology. Cold Spring Harb Perspect Biol. 2016, 8, a021873. [CrossRef]
  190. Friis Wang N, Bogstad JW, Petersen MR, Pinborg A, Yding Andersen C, Løssl K. Androgen and inhibin B levels during ovarian stimulation before and after 8 weeks of low-dose hCG priming in women with low ovarian reserve. Hum Reprod. 2023:dead134. [CrossRef]
  191. Sehested A, Juul AA, Andersson AM, Petersen JH, Jensen TK, Müller J, Skakkebaek NE. Serum inhibin A and inhibin B in healthy prepubertal, pubertal, and adolescent girls and adult women: relation to age, stage of puberty, menstrual cycle, follicle-stimulating hormone, luteinizing hormone, and estradiol levels. J Clin Endocrinol Metab. 2000, 85, 1634–40. [CrossRef]
  192. Hillier, SG. Paracrine support of ovarian stimulation. Mol Hum Reprod. 2009, 15, 843–50. [Google Scholar] [CrossRef]
  193. Canipari R, Cellini V, Cecconi S. The ovary feels fine when paracrine and autocrine networks cooperate with gonadotropins in the regulation of folliculogenesis. Curr Pharm Des. 2012, 18, 245–55. [CrossRef]
  194. Padmanabhan V, Cardoso RC. Neuroendocrine, autocrine, and paracrine control of follicle-stimulating hormone secretion. Mol Cell Endocrinol. 2020, 500:110632. [CrossRef]
  195. Takahashi T, Ohnishi J. Molecular mechanism of follicle rupture during ovulation. Zoolog Sci. 1995, 12, 359–65. [CrossRef]
  196. Canipari R, Strickland S. Studies on the hormonal regulation of plasminogen activator production in the rat ovary. Endocrinology. 1986, 118, 1652–9. [CrossRef]
  197. Wang C, Leung A. Gonadotropins regulate plasminogen activator production by rat granulosa cells. Endocrinology. 1983, 112, 1201–7. [CrossRef]
  198. Lumsden MA, Kelly RW, Templeton AA, Van Look PF, Swanston IA, Baird DT. Changes in the concentration of prostaglandins in preovulatory human follicles after administration of hCG. J Reprod Fertil. 1986, 77, 119–24. [CrossRef]
  199. Espey LL, Tanaka N, Adams RF, Okamura H. Ovarian hydroxyeicosatetraenoic acids compared with prostanoids and steroids during ovulation in rats. Am J Physiol. 1991, 260(2 Pt 1): E163-9. [CrossRef]
  200. Borba VV, Zandman-Goddard G, Shoenfeld Y. Prolactin and autoimmunity: The hormone as an inflammatory cytokine. Best Pract Res Clin Endocrinol Metab. 2019, 33, 101324. [CrossRef]
  201. Hu S, Duggavathi R, Zadworny D. Regulatory Mechanisms Underlying the Expression of Prolactin Receptor in Chicken Granulosa Cells. PLoS One. 2017, 12, e0170409. [CrossRef]
  202. Yang R, Duan C, Zhang S, Liu Y, Zhang Y. Prolactin Regulates Ovine Ovarian Granulosa Cell Apoptosis by Affecting the Expression of MAPK12 Gene. Int J Mol Sci. 2023, 24, 10269. [CrossRef]
  203. Legro, RS. The new International Federation of Gynecology and Obstetrics (FIGO) classification of ovulatory disorders: getting from here to there. Fertil Steril. 2023, 119, 560–561. [Google Scholar] [CrossRef]
  204. Walker MH, Tobler KJ. Female Infertility. [Updated 2022 Dec 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556033/.
  205. Munro MG, Balen AH, Cho S, Critchley HOD, Díaz I, Ferriani R, Henry L, Mocanu E, van der Spuy ZM; FIGO Committee on Menstrual Disorders and Related Health Impacts, and FIGO Committee on Reproductive Medicine, Endocrinology, and Infertility. The FIGO ovulatory disorders classification system. Int J Gynaecol Obstet. 2022, 159, 1–20. [CrossRef]
  206. Agents stimulating gonadal function in the human. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1973, 514:1-30.
  207. Urman B, Yakin K. Ovulatory disorders and infertility. J Reprod Med. 2006, 51, 267–82.
  208. Azziz, R. Introduction: Determinants of polycystic ovary syndrome. Fertil Steril. 2016, 106, 4–5. [Google Scholar] [CrossRef] [PubMed]
  209. Deswal R, Narwal V, Dang A, Pundir CS. The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. J Hum Reprod Sci. 2020, 13, 261–271. [CrossRef]
  210. Liu J, Wu Q, Hao Y, Jiao M, Wang X, Jiang S, Han L.. Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study Hum Reprod. 2021, 36, 1108–1119. [CrossRef]
  211. Shrivastava S, Conigliaro RL.. Polycystic Ovarian Syndrome. Med Clin North Am. 2023, 107, 227–234. [CrossRef]
  212. Smet ME, McLennan A. Rotterdam criteria, the end. Australas J Ultrasound Med. 2018, 21, 59–60. [CrossRef]
  213. Szukiewicz D, Trojanowski S, Kociszewska A, Szewczyk G. Modulation of the Inflammatory Response in Polycystic Ovary Syndrome (PCOS)-Searching for Epigenetic Factors. Int J Mol Sci. 2022, 23, 14663. [CrossRef]
  214. Harada, M. Pathophysiology of polycystic ovary syndrome revisited: Current understanding and perspectives regarding future research. Reprod Med Biol. 2022, 21, e12487. [Google Scholar] [CrossRef]
  215. Davoudi Z, Araghi F, Vahedi M, Mokhtari N, Gheisari M. Prolactin Level in Polycystic Ovary Syndrome (PCOS): An approach to the diagnosis and management. Acta Biomed. 2021, 92, e2021291. [CrossRef]
  216. Kim SI, Yoon JH, Park DC, Yang SH, Kim YI. What is the optimal prolactin cutoff for predicting the presence of a pituitary adenoma in patients with polycystic ovary syndrome? Int J Med Sci. 2023, 20, 463–467. [CrossRef]
  217. Liu YX, Peng XR, Chen YJ, Carrico W, Ny T. Prolactin delays gonadotrophin-induced ovulation and down-regulates expression of plasminogen-activator system in ovary. Hum Reprod. 1997, 12, 2748–55. [CrossRef]
  218. Chang S, Copperman AB. New insights into human prolactin pathophysiology: genomics and beyond. Curr Opin Obstet Gynecol. 2019, 31, 207–211. [CrossRef]
  219. Thapa S, Bhusal K. Hyperprolactinemia. [Updated 2023 Jul 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537331/.
  220. Stojkovic M, Radmanovic B, Jovanovic M, Janjic V, Muric N, Ristic DI. Risperidone Induced Hyperprolactinemia: From Basic to Clinical Studies. Front Psychiatry. 2022, 13:874705. [CrossRef]
  221. Malik AA, Aziz F, Beshyah SA, Aldahmani KM. Aetiologies of Hyperprolactinaemia: A retrospective analysis from a tertiary healthcare centre. Sultan Qaboos Univ Med J. 2019, 19, e129–e134. [CrossRef]
  222. Aliberti L, Gagliardi I, Dorizzi RM, Pizzicotti S, Bondanelli M, Zatelli MC, Ambrosio MR. Hypeprolactinemia: still an insidious diagnosis. Endocrine. 2021, 72, 928–931. [CrossRef]
  223. Grattan DR, Steyn FJ, Kokay IC, Anderson GM, Bunn SJ. Pregnancy-induced adaptation in the neuroendocrine control of prolactin secretion. J Neuroendocrinol. 2008, 20, 497–507. [CrossRef]
  224. Kirk SE, Xie TY, Steyn FJ, Grattan DR, Bunn SJ. Restraint stress increases prolactin-mediated phosphorylation of signal transducer and activator of transcription 5 in the hypothalamus and adrenal cortex in the male mouse. J Neuroendocrinol. 2017, 29. [CrossRef]
  225. Hackney AC, Saeidi A. The thyroid axis, prolactin, and exercise in humans. Curr Opin Endocr Metab Res. 2019, 9:45-50. [CrossRef]
  226. Mogavero MP, Cosentino FII, Lanuzza B, Tripodi M, Lanza G, Aricò D, DelRosso LM, Pizza F, Plazzi G, Ferri R. Increased Serum Prolactin and Excessive Daytime Sleepiness: An Attempt of Proof-of-Concept Study. Brain Sci. 2021, 11, 1574. [CrossRef]
  227. Kapcala LP, Lakshmanan MC. Thoracic stimulation and prolactin secretion. J Endocrinol Invest. 1989, 12, 815–21. [CrossRef]
  228. Nteeba J, Kubota K, Wang W, Zhu H, Vivian J, Dai G, Soares M. Pancreatic prolactin receptor signaling regulates maternal glucose homeostasis. J Endocrinol. 2019:JOE-18-0518.R2. [CrossRef]
  229. Krüger TH, Hartmann U, Schedlowski M. Prolactinergic and dopaminergic mechanisms underlying sexual arousal and orgasm in humans. World J Urol. 2005, 23, 130–8. [CrossRef]
  230. Samperi I, Lithgow K, Karavitaki N. Hyperprolactinaemia. J Clin Med. 2019, 8, 2203. [CrossRef]
  231. Shukla P, Bulsara KR, Luthra P. Pituitary Hyperplasia in Severe Primary Hypothyroidism: A Case Report and Review of the Literature. Case Rep Endocrinol. 2019, 2019:2012546. [CrossRef]
  232. Dourado M, Cavalcanti F, Vilar L, Cantilino A. Relationship between Prolactin, Chronic Kidney Disease, and Cardiovascular Risk. Int J Endocrinol. 2020, 2020:9524839. [CrossRef]
  233. Adachi N, Lei B, Deshpande G, Seyfried FJ, Shimizu I, Nagaro T, Arai T. Uraemia suppresses central dopaminergic metabolism and impairs motor activity in rats. Intensive Care Med. 2001, 27, 1655–60. [CrossRef]
  234. Jha SK, Kannan S. Serum prolactin in patients with liver disease in comparison with healthy adults: A preliminary cross-sectional study. Int J Appl Basic Med Res. 2016, 6, 8–10. [CrossRef]
  235. Pekic S, Miljic D, Popovic V. Hypopituitarism Following Cranial Radiotherapy. [Updated 2021 Aug 9]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532082/. 5320.
  236. Niculescu DA, Gheorghiu ML, Poiana C. Radiotherapy in aggressive or dopamine agonists resistant prolactinomas; is it still worthwhile? Eur J Endocrinol. 2023, 188, R88–R97. [CrossRef]
  237. Rutberg L, Fridén B, Karlsson AK. Amenorrhoea in newly spinal cord injured women: an effect of hyperprolactinaemia? Spinal Cord. 2008, 46, 189–91. [CrossRef]
  238. Arinola E, Adeleye JO, Lawal OA, Oluwakemi BA. Hyperprolactinemia following traumatic myelopathy. African Journal of Endocrinology and Metabolism. 2022, 12, 93–95. [CrossRef]
  239. Hermann AL, Fell GL, Kemény LV, Fung CY, Held KD, Biggs PJ, Rivera PD, Bilbo SD, Igras V, Willers H, Kung J, Gheorghiu L, Hideghéty K, Mao J, Woolf CJ, Fisher DE. β-Endorphin mediates radiation therapy fatigue. Sci Adv. 2022, 8, eabn6025. [CrossRef]
  240. Panahi Y, Fathi E, Shafiian MA. The link between seizures and prolactin: A study on the effects of anticonvulsant medications on hyperprolactinemia in rats. Epilepsy Res. 2023, 196:107206. [CrossRef]
  241. Bahceci M, Tuzcu A, Bahceci S, Tuzcu S. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest. 2003, 26, 655–659. [CrossRef]
  242. Le Bescont A, Vitte AL, Debernardi A, Curtet S, Buchou T, Vayr J, de Reyniès A, Ito A, Guardiola P, Brambilla C, Yoshida M, Brambilla E, Rousseaux S, Khochbin S. Receptor-Independent Ectopic Activity of Prolactin Predicts Aggressive Lung Tumors and Indicates HDACi-Based Therapeutic Strategies. Antioxid Redox Signal. 2015, 23, 1–14. [CrossRef]
  243. Letson GW, Moore DC. Galactorrhea secondary to chest wall surgery in an adolescent. J Adolesc Health Care. 1984, 5, 277–8. [CrossRef]
  244. Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol. 2008, 22(2 Suppl):46-55. [CrossRef]
  245. Junqueira DR, Bennett D, Huh SY, Casañas I Comabella C. Clinical Presentations of Drug-Induced Hyperprolactinaemia: A Literature Review. Pharmaceut Med. 2023, 37, 153–166. [CrossRef]
  246. Kim S, Jeong JH, Um YH, Kim TW, Seo HJ, Hong SC. Prolactin Level Changes according to Atypical Antipsychotics Use: A Study Based on Clinical Data Warehouse. Clin Psychopharmacol Neurosci. 2023, 21, 769–777. [CrossRef]
  247. Bhattacharjee S, Biswas R, Mandal N. Selective serotonin reuptake inhibitor-induced galactorrhea with hyperprolactinemia. Indian J Psychiatry. 2021, 63, 613–616. [CrossRef]
  248. Ashbury JE, Lévesque LE, Beck PA, Aronson KJ. Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants, Prolactin and Breast Cancer. Front Oncol. 2012, 2:177. [CrossRef]
  249. Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007, 3, 929–51.
  250. Rodier C, Courbière B, Fernandes S, Vermalle M, Florence B, Resseguier N, Brue T, Cuny T. Metoclopramide Test in Hyperprolactinemic Women With Polycystic Ovarian Syndrome: Old Wine Into New Bottles? Front Endocrinol (Lausanne). 2022, 13:832361. [CrossRef]
  251. Kertesz E, Somoza GM, D'Eramo JL, Libertun C. Further evidence for endogenous hypothalamic serotonergic neurons involved in the cimetidine-induced prolactin release in the rat. Brain Res. 1987, 413, 10–4. [CrossRef]
  252. Meltzer HY, Maes M, Lee MA. The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine. Psychopharmacology (Berl). 1993, 112(1 Suppl):S95-104. [CrossRef]
  253. Gupta M, Al Khalili Y. Methyldopa. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.
  254. Kelley SR, Kamal TJ, Molitch ME. Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia. Am J Physiol. 1996, 270(1 Pt 1):E96-100. [CrossRef]
  255. Veselinović T, Schorn H, Vernaleken IB, Schiffl K, Klomp M, Gründer G. Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. J Clin Psychopharmacol. 2011, 31, 214–20. [CrossRef]
  256. Ren N, Carratala-Ros C, Ecevitoglu A, Rotolo RA, Edelstein GA, Presby RE, Stevenson IH, Chrobak JJ, Salamone JD. Effects of the dopamine depleting agent tetrabenazine on detailed temporal parameters of effort-related choice responding. J Exp Anal Behav. 2022, 117, 331–345. [CrossRef]
  257. Enjalbert A, Ruberg M, Arancibia S, Priam M, Kordon C. Endogenous opiates block dopamine inhibition of prolactin secretion in vitro. Nature 1979, 280:595–597. [CrossRef]
  258. Arbogast LA, Voogt JL.. Endogenous opioid peptides contribute to suckling-induced prolactin release by suppressing tyrosine hydroxylase activity and messenger ribonucleic acid levels in tuberoinfundibular dopaminergic neurons. Endocrinology. 1998, 139, 2857–62. [CrossRef]
  259. Chourpiliadi C, Paparodis R. Physiology, Pituitary Issues During Pregnancy. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.
  260. Perez PA, Petiti JP, Picech F, Guido CB, dV Sosa L, Grondona E, Mukdsi JH, De Paul AL, Torres AI, Gutierrez S. Estrogen receptor β regulates the tumoral suppressor PTEN to modulate pituitary cell growth. J Cell Physiol. 2018, 233, 1402–1413. [CrossRef]
  261. Lyons DJ, Broberger C. TIDAL WAVES: Network mechanisms in the neuroendocrine control of prolactin release. Front Neuroendocrinol. 2014 Oct;35, 420-38. [CrossRef]
  262. Thörn Pérez C, Ferraris J, van Lunteren JA, Hellysaz A, Iglesias MJ, Broberger C. Adaptive Resetting of Tuberoinfundibular Dopamine (TIDA) Network Activity during Lactation in Mice. J Neurosci. 2020, 40, 3203–3216. [CrossRef]
  263. Lyons DJ, Ammari R, Hellysaz A, Broberger C. Serotonin and Antidepressant SSRIs Inhibit Rat Neuroendocrine Dopamine Neurons: Parallel Actions in the Lactotrophic Axis. J Neurosci. 2016, 36, 7392–406. [CrossRef]
  264. Bernard V, Lamothe S, Beau I, Guillou A, Martin A, Le Tissier P, Grattan D, Young J, Binart N. Autocrine actions of prolactin contribute to the regulation of lactotroph function in vivo. FASEB J. 2018, 32, 4791–4797. [CrossRef]
  265. Yatavelli RKR, Bhusal K. Prolactinoma. [Updated 2023 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459347. 4593.
  266. Lyu L, Yin S, Hu Y, Chen C, Jiang Y, Yu Y, Ma W, Wang Z, Jiang S, Zhou P. Hyperprolactinemia in clinical non-functional pituitary macroadenomas: A STROBE-compliant study. Medicine (Baltimore). 2020, 99, e22673. [CrossRef]
  267. Bergsneider M, Mirsadraei L, Yong WH, Salamon N, Linetsky M, Wang MB, McArthur DL, Heaney AP. The pituitary stalk effect: is it a passing phenomenon? J Neurooncol. 2014, 117, 477–84. [CrossRef]
  268. Schury MP, Adigun R. Sheehan Syndrome. [Updated 2023 Sep 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459166/. 4591.
  269. Montejo ÁL, Arango C, Bernardo M, Carrasco JL, Crespo-Facorro B, Cruz JJ, Del Pino-Montes J, García-Escudero MA, García-Rizo C, González-Pinto A, Hernández AI, Martín-Carrasco M, Mayoral-Cleries F, Mayoral-van Son J, Mories MT, Pachiarotti I, Pérez J, Ros S, Vieta E. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017, 45:25-34. [CrossRef]
  270. García Cano AM, Rosillo M, Gómez Lozano A, Jiménez Mendiguchía L, Marchán Pinedo M, Rodríguez Torres A, Araujo-Castro M. Pharmacological hyperprolactinemia: a retrospective analysis of 501 hyperprolactinemia cases in primary care setting. Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov 1. [CrossRef]
  271. Montejo ÁL, Arango C, Bernardo M, Carrasco JL, Crespo-Facorro B, Cruz JJ, Del Pino J, García Escudero MA, García Rizo C, González-Pinto A, Hernández AI, Martín Carrasco M, Mayoral Cleries F, Mayoral van Son J, Mories MT, Pachiarotti I, Ros S, Vieta E. Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. Rev Psiquiatr Salud Ment. 2016, 9, 158–73 English, Spanish. [CrossRef]
  272. Wiciński M, Malinowski B, Puk O, Socha M, Słupski M. Methyldopa as an inductor of postpartum depression and maternal blues: A review. Biomed Pharmacother. 2020, 127:110196. [CrossRef]
  273. Yoshimura Y, Nakamura Y, Yamada H, Ando M, Ubukata Y, Oda T, Suzuki M. Possible contribution of prolactin in the process of ovulation and oocyte maturation. Horm Res. 1991, 35 Suppl 1:22-32. [CrossRef]
  274. Stocco, C. The long and short of the prolactin receptor: the corpus luteum needs them both!. Biol Reprod. 2012, 86, 85. [Google Scholar] [CrossRef] [PubMed]
  275. Ezoe K, Fujiwara N, Miki T, Kato K. Post-warming culture of human vitrified blastocysts with prolactin improves trophoblast outgrowth. Reprod Biol Endocrinol. 2023, 21, 6. [CrossRef]
  276. Alila HW, Rogo KO, Gombe S. Effects of prolactin on steroidogenesis by human luteal cells in culture. Fertil Steril. 1987, 47, 947–55.
  277. Grattan DR, Jasoni CL, Liu X, Anderson GM, Herbison AE. Prolactin regulation of gonadotropin-releasing hormone neurons to suppress luteinizing hormone secretion in mice. Endocrinology. 2007, 148, 4344–51. [CrossRef]
  278. Brown RS, Piet R, Herbison AE, Grattan DR. Differential actions of prolactin on electrical activity and intracellular signal transduction in hypothalamic neurons. Endocrinology. 2012, 153, 2375–84. [CrossRef]
  279. Cortasa SA, Schmidt AR, Proietto S, Corso MC, Inserra PIF, Giorgio NPD, Lux-Lantos V, Vitullo AD, Halperin J, Dorfman VB. Hypothalamic GnRH expression and pulsatility depends on a balance of prolactin receptors in the plains vizcacha, Lagostomus maximus. J Comp Neurol. 2023, 531, 720–742. [CrossRef]
  280. Xie Q, Kang Y, Zhang C, Xie Y, Wang C, Liu J, Yu C, Zhao H, Huang D. The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction. Front Endocrinol (Lausanne). 2022, 13:925206. [CrossRef]
  281. Iwasa T, Matsuzaki T, Yano K, Mayila Y, Irahara M. The roles of kisspeptin and gonadotropin inhibitory hormone in stress-induced reproductive disorders. Endocr J. 2018, 65, 133–140. [CrossRef]
  282. Zeydabadi Nejad S, Ramezani Tehrani F, Zadeh-Vakili A. The Role of Kisspeptin in Female Reproduction. Int J Endocrinol Metab. 2017, 15, e44337. [CrossRef]
  283. Franssen D, Tena-Sempere M. The kisspeptin receptor: A key G-protein-coupled receptor in the control of the reproductive axis. Best Pract Res Clin Endocrinol Metab. 2018, 32, 107–123. [CrossRef]
  284. d'Anglemont de Tassigny X, Colledge WH. The role of kisspeptin signaling in reproduction. Physiology (Bethesda). 2010, 25, 207–17, Erratum in: Physiology (Bethesda). 2010, 25, 378. [CrossRef]
  285. Goodman RL, Hileman SM, Nestor CC, Porter KL, Connors JM, Hardy SL, Millar RP, Cernea M, Coolen LM, Lehman MN. Kisspeptin, neurokinin B, and dynorphin act in the arcuate nucleus to control activity of the GnRH pulse generator in ewes. Endocrinology. 2013, 154, 4259–69. [CrossRef]
  286. Moore AM, Coolen LM, Lehman MN. Kisspeptin/Neurokinin B/Dynorphin (KNDy) cells as integrators of diverse internal and external cues: evidence from viral-based monosynaptic tract-tracing in mice. Sci Rep. 2019, 9, 14768. [CrossRef]
  287. Merkley CM, Porter KL, Coolen LM, Hileman SM, Billings HJ, Drews S, Goodman RL, Lehman MN. KNDy (kisspeptin/neurokinin B/dynorphin) neurons are activated during both pulsatile and surge secretion of LH in the ewe. Endocrinology. 2012, 153, 5406–14. [CrossRef]
  288. Mittelman-Smith MA, Krajewski-Hall SJ, McMullen NT, Rance NE. Neurokinin 3 Receptor-Expressing Neurons in the Median Preoptic Nucleus Modulate Heat-Dissipation Effectors in the Female Rat. Endocrinology. 2015, 156, 2552–62. [CrossRef]
  289. Duittoz A, Cayla X, Fleurot R, Lehnert J, Khadra A. Gonadotrophin-releasing hormone and kisspeptin: It takes two to tango. J Neuroendocrinol. 2021, 33, e13037. [CrossRef]
  290. Constantin, S. Physiology of the gonadotrophin-releasing hormone (GnRH) neurone: studies from embryonic GnRH neurones. J Neuroendocrinol. 2011, 23, 542–53. [Google Scholar] [CrossRef]
  291. d'Anglemont de Tassigny X, Fagg LA, Carlton MB, Colledge WH. Kisspeptin can stimulate gonadotropin-releasing hormone (GnRH) release by a direct action at GnRH nerve terminals. Endocrinology. 2008, 149, 3926–32. [CrossRef]
  292. Tng, EL. Kisspeptin signalling and its roles in humans. Singapore Med J. 2015, 56, 649–56. [Google Scholar] [CrossRef] [PubMed]
  293. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS Jr, Shagoury JK, Bo-Abbas Y, Kuohung W, Schwinof KM, Hendrick AG, Zahn D, Dixon J, Kaiser UB, Slaugenhaupt SA, Gusella JF, O'Rahilly S, Carlton MB, Crowley WF Jr, Aparicio SA, Colledge WH. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003, 349, 1614–27. [CrossRef]
  294. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A. 2003, 100, 10972–6. [CrossRef]
  295. Funes S, Hedrick JA, Vassileva G, Markowitz L, Abbondanzo S, Golovko A, Yang S, Monsma FJ, Gustafson EL.. The KiSS-1 receptor GPR54 is essential for the development of the murine reproductive system. Biochem Biophys Res Commun. 2003, 312, 1357–63. [CrossRef]
  296. Teles MG, Bianco SD, Brito VN, Trarbach EB, Kuohung W, Xu S, Seminara SB, Mendonca BB, Kaiser UB, Latronico AC. A GPR54-activating mutation in a patient with central precocious puberty. N Engl J Med. 2008, 358, 709–15. [CrossRef]
  297. Kaiser M, Jaillardon L. Pathogenesis of the crosstalk between reproductive function and stress in animals-part 1: Hypothalamo-pituitary-adrenal axis, sympatho-adrenomedullary system and kisspeptin. Reprod Domest Anim. 2023, 58 Suppl 2:176-183. [CrossRef]
  298. Brown RS, Herbison AE, Grattan DR. Prolactin regulation of kisspeptin neurones in the mouse brain and its role in the lactation-induced suppression of kisspeptin expression. J Neuroendocrinol. 2014, 26, 898–908. [CrossRef]
  299. Araujo-Lopes R, Crampton JR, Aquino NS, Miranda RM, Kokay IC, Reis AM, Franci CR, Grattan DR, Szawka RE. Prolactin regulates kisspeptin neurons in the arcuate nucleus to suppress LH secretion in female rats. Endocrinology. 2014, 155, 1010–20. [CrossRef]
  300. Kokay IC, Petersen SL, Grattan DR. Identification of prolactin-sensitive GABA and kisspeptin neurons in regions of the rat hypothalamus involved in the control of fertility. Endocrinology. 2011, 152, 526–35. [CrossRef]
  301. Li Q, Rao A, Pereira A, Clarke IJ, Smith JT. Kisspeptin cells in the ovine arcuate nucleus express prolactin receptor but not melatonin receptor. J Neuroendocrinol. 2011, 23, 871–82. [CrossRef]
  302. Gustafson P, Ladyman SR, McFadden S, Larsen C, Khant Aung Z, Brown RSE, Bunn SJ, Grattan DR. Prolactin receptor-mediated activation of pSTAT5 in the pregnant mouse brain. J Neuroendocrinol. 2020, 32, e12901. [CrossRef]
  303. Calik-Ksepka A, Stradczuk M, Czarnecka K, Grymowicz M, Smolarczyk R. Lactational Amenorrhea: Neuroendocrine Pathways Controlling Fertility and Bone Turnover. Int J Mol Sci. 2022, 23, 1633. [CrossRef]
  304. Grattan DR, Szawka RE. Kisspeptin and Prolactin. Semin Reprod Med. 2019, 37, 93–104. [CrossRef]
  305. Hara T, Kanasaki H, Tumurbaatar T, Oride A, Okada H, Kyo S. Role of kisspeptin and Kiss1R in the regulation of prolactin gene expression in rat somatolactotroph GH3 cells. Endocrine. 2019, 63, 101–111. [CrossRef]
  306. Ammari R, Broberger C. Pre- and post-synaptic modulation by GABAB receptors of rat neuroendocrine dopamine neurones. J Neuroendocrinol. 2020, 32, e12881. [CrossRef]
  307. Aquino NSS, Kokay IC, Perez CT, Ladyman SR, Henriques PC, Silva JF, Broberger C, Grattan DR, Szawka RE. Kisspeptin Stimulation of Prolactin Secretion Requires Kiss1 Receptor but Not in Tuberoinfundibular Dopaminergic Neurons. Endocrinology. 2019, 160, 522–533. [CrossRef]
  308. Ribeiro AB, Leite CM, Kalil B, Franci CR, Anselmo-Franci JA, Szawka RE. Kisspeptin regulates tuberoinfundibular dopaminergic neurones and prolactin secretion in an oestradiol-dependent manner in male and female rats. J Neuroendocrinol. 2015, 27, 88–99. [CrossRef]
  309. Sonigo C, Bouilly J, Carré N, Tolle V, Caraty A, Tello J, Simony-Conesa FJ, Millar R, Young J, Binart N. Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest. 2012, 122, 3791–5. [CrossRef]
  310. Uenoyama Y, Pheng V, Tsukamura H, Maeda KI. The roles of kisspeptin revisited: inside and outside the hypothalamus. J Reprod Dev. 2016, 62, 537–545. [CrossRef]
  311. Yang F, Zhao S, Wang P, Xiang W. Hypothalamic neuroendocrine integration of reproduction and metabolism in mammals. J Endocrinol. 2023, 258, e230079. [CrossRef]
  312. Lee MS, Ben-Rafael Z, Meloni F, Mastroianni L Jr, Flickinger GL.. Relationship of human oocyte maturity, fertilization, and cleavage to follicular fluid prolactin and steroids. J In Vitro Fert Embryo Transf. 1987, 4, 168–72. [CrossRef]
  313. Reinthaller A, Deutinger J, Riss P, Müller-Tyl E, Fischl F, Bieglmayer C, Janisch H. Relationship between the steroid and prolactin concentration in follicular fluid and the maturation and fertilization of human oocytes. J In Vitro Fert Embryo Transf. 1987, 4, 228–31. [CrossRef]
  314. Subramanian MG, Sacco AG, Moghissi KS, Magyar DM, Hayes MF, Lawson DM, Gala RR. Human follicular fluid: prolactin is biologically active and ovum fertilization correlates with estradiol concentration. J In Vitro Fert Embryo Transf. 1988, 5, 129–33. [CrossRef]
  315. Lindner C, Lichtenberg V, Westhof G, Braendle W, Bettendorf G. Endocrine parameters of human follicular fluid and fertilization capacity of oocytes. Horm Metab Res. 1988, 20, 243–6. [CrossRef]
  316. Laufer N, Botero-Ruiz W, DeCherney AH, Haseltine F, Polan ML, Behrman HR. Gonadotropin and prolactin levels in follicular fluid of human ova successfully fertilized in vitro. J Clin Endocrinol Metab. 1984, 58, 430–4. [CrossRef]
  317. Wyse BA, Fuchs Weizman N, Defer M, Montbriand J, Szaraz P, Librach C. The follicular fluid adipocytokine milieu could serve as a prediction tool for fertility treatment outcomes. Reprod Biomed Online. 2021, 43, 738–746. [CrossRef]
  318. Romão GS, Ferriani RA, Moura MD, Martins AR. Screening for prolactin isoforms in the follicular fluid of patients undergoing in vitro fertilization. Gynecol Obstet Invest. 2002, 54, 46–9. [CrossRef]
  319. Castilla A, García C, Cruz-Soto M, Martínez de la Escalera G, Thebault S, Clapp C. Prolactin in ovarian follicular fluid stimulates endothelial cell proliferation. J Vasc Res. 2010, 47, 45–53. [CrossRef]
  320. Amin M, Gragnoli C. The prolactin receptor gene (PRLR) is linked and associated with the risk of polycystic ovarian syndrome. J Ovarian Res. 2023, 16, 222. [CrossRef]
  321. Alkharusi A, AlMuslahi A, AlBalushi N, AlAjmi R, AlRawahi S, AlFarqani A, Norstedt G, Zadjali F. Connections between prolactin and ovarian cancer. PLoS One. 2021, 16, e0255701. [CrossRef]
  322. Cho A, Vila G, Marik W, Klotz S, Wolfsberger S, Micko A. Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else. Front Endocrinol (Lausanne). 2022, 13: 901385. [CrossRef]
  323. Cheng JS, Salinas R, Molinaro A, Chang EF, Kunwar S, Blevins L, Aghi MK. A predictive algorithm for evaluating elevated serum prolactin in patients with a sellar mass. J Clin Neurosci. 2015, 22, 155–60. [CrossRef]
  324. Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, Bronstein M, Chanson P, Fukuoka H, Gadelha M, Greenman Y, Gurnell M, Ho KKY, Honegger J, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Lodish M, Maiter D, Marcus HJ, McCormack A, Molitch M, Muir CA, Neggers S, Pereira AM, Pivonello R, Post K, Raverot G, Salvatori R, Samson SL, Shimon I, Spencer-Segal J, Vila G, Wass J, Melmed S. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023, 19, 722–740, Erratum in: Nat Rev Endocrinol. 2023 Oct 17. [CrossRef]
  325. Chanson P, Borson-Chazot F, Chabre O, Estour B. Drug treatment of hyperprolactinemia. Ann Endocrinol (Paris). 2007, 68(2-3):113-7. [CrossRef]
  326. Concepción-Zavaleta MJ, Coronado-Arroyo JC, Quiroz-Aldave JE, Durand-Vásquez MDC, Ildefonso-Najarro SP, Rafael-Robles LDP, Concepción-Urteaga LA, Gamarra-Osorio ER, Suárez-Rojas J, Paz-Ibarra J. Endocrine factors associated with infertility in women: an updated review. Expert Rev Endocrinol Metab. 2023, 18, 399–417. [CrossRef]
  327. Hoskova K, Kayton Bryant N, Chen ME, Nachtigall LB, Lippincott MF, Balasubramanian R, Seminara SB. Kisspeptin Overcomes GnRH Neuronal Suppression Secondary to Hyperprolactinemia in Humans. J Clin Endocrinol Metab. 2022, 107, e3515–e3525, Erratum in: J Clin Endocrinol Metab. 2022 May 18. [CrossRef]
  328. Rezaei-Tazangi F, Kooshesh L, Tayyebiazar A, Taghizabet N, Tavakoli A, Hassanpour A, Aliakbari F, Kharazinejad E, Sharifi AM. Effects of kisspeptin on the maturation of human ovarian primordial follicles in vitro. Zygote. 2023:1-5. [CrossRef]
  329. Chutpiboonwat P, Yenpinyosuk K, Sridama V, Kunjan S, Klaimukh K, Snabboon T. Macroprolactinemia in patients with hyperprolactinemia: an experience from a single tertiary center. Pan Afr Med J. 2020, 36:8. [CrossRef]
  330. Richa V, Rahul G, Sarika A. Macroprolactin; a frequent cause of misdiagnosed hyperprolactinemia in clinical practice. J Reprod Infertil. 2010, 11, 161–7.
  331. Che Soh NAA, Yaacob NM, Omar J, Mohammed Jelani A, Shafii N, Tuan Ismail TS, Wan Azman WN, Ghazali AK. Global Prevalence of Macroprolactinemia among Patients with Hyperprolactinemia: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2020, 17, 8199. [CrossRef]
  332. Chen Y, Wang H, Yang W, Jin W, Yu W, Wang W, Zhang K, Song G. A New Method of Using Polyethylene Glycol (PEG) Precipitation of Macroprolactin to Detect Genuine Hyperprolactinemia. J Clin Lab Anal. 2016, 30, 1169–1174. [CrossRef]
  333. Shimatsu A, Hattori N. Macroprolactinemia: diagnostic, clinical, and pathogenic significance. Clin Dev Immunol. 2012, 2012:167132. [CrossRef]
Preprints 96142 g001aPreprints 96142 g001b
Figure 1. Structure of the prolactin (PRL) molecule. A. The 199 amino acid chain. There are three intramolecular disulfide bonds between six cysteine residues in the human prolactin chain: Cys4-Cys11, Cys58-Cys174, and Cys191-Cys199. B. The tertiary structure. Each PRL molecule contains four α-helical domains (D) and two binding sites (BSs) (BS 1 involves helices 1 and 4, while BS2 encompasses helices 1 and 3) [5,45]. Loops between the helices and three intermolecular disulfide bonds between six cysteine residues are also marked.
Figure 1. Structure of the prolactin (PRL) molecule. A. The 199 amino acid chain. There are three intramolecular disulfide bonds between six cysteine residues in the human prolactin chain: Cys4-Cys11, Cys58-Cys174, and Cys191-Cys199. B. The tertiary structure. Each PRL molecule contains four α-helical domains (D) and two binding sites (BSs) (BS 1 involves helices 1 and 4, while BS2 encompasses helices 1 and 3) [5,45]. Loops between the helices and three intermolecular disulfide bonds between six cysteine residues are also marked.
Preprints 96142 g001aPreprints 96142 g001b
Preprints 96142 g002
Figure 2. Examples of common isoforms of the human prolactin receptor (PRLR): long form (LF), intermediate form (IF), short isoforms (S1a, S1b), isoform ΔS1, and – as a representative of the soluble forms – the prolactin binding protein (PRLBP) [60,62,67,68,70]. aa – amino acid count; Box-1, Box-2 – the proline-rich and hydrophobic regions in the intracellular domain of cytokine receptor 1 and 2, respectively; C-C – carbon-carbon bond; D1, D2 – the two fibronectin type III domains; ECR – extracellular region; ICR – intracellular (cytoplasmic) region; TMR/TMD – transmembrane region/transmembrane domain; WSXWS – a conserved amino acid sequence (WS motif) serving as a molecular switch involved in PRLR activation.
Figure 2. Examples of common isoforms of the human prolactin receptor (PRLR): long form (LF), intermediate form (IF), short isoforms (S1a, S1b), isoform ΔS1, and – as a representative of the soluble forms – the prolactin binding protein (PRLBP) [60,62,67,68,70]. aa – amino acid count; Box-1, Box-2 – the proline-rich and hydrophobic regions in the intracellular domain of cytokine receptor 1 and 2, respectively; C-C – carbon-carbon bond; D1, D2 – the two fibronectin type III domains; ECR – extracellular region; ICR – intracellular (cytoplasmic) region; TMR/TMD – transmembrane region/transmembrane domain; WSXWS – a conserved amino acid sequence (WS motif) serving as a molecular switch involved in PRLR activation.
Preprints 96142 g002
Preprints 96142 g003
Figure 3. Simplified scheme of signaling via the prolactin receptor, its long isoform (PRLR-LF) has been included for better clarity. The main signaling pathways and the typical known effects of their activation are marked in different colors. In canonical (JAK/STAT) signaling (shades of blue), ligand binding to the PRLR results in stimulation of the tyrosine kinase activity of Janus kinase 2 (JAK2) and subsequent multiple tyrosine residues phosphorylation (P) and activation of signal transducer and activator of transcription (STATs) proteins, in particular STAT5 (JAK2/STAT5 signaling) [73,74]. The lack of a physical association with STAT5a may redirect to signaling via RUSH/SMARCA3 (red) with gene regulation mainly through chromatin remodeling. The presence of transcription factors RUSH-1α and RUSH-1β as well as SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A, member 3 (SMARCA3) in both cytoplasm and nucleus suggests their bidirectional passage across the nuclear membrane (marked with a double-sided arrow with a dotted line) [76]. Transcription of target genes also occurs after activation of the Ras kinases/Raf kinases/mitogen-activated protein kinase/extracellular signal-regulated kinase ½ (Ras/Raf/MAPK/ERK1/2) [75,76] and the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3-Kinase/AKT/mTOR) [76,77] pathways. These signal paths are integrated with each other on many levels. * Activation of the PRLR may occur due to the action of agonists other than prolactin (e.g., hPL,GH, and IL-2). Other abbreviations: FAK – focal adhesion kinase; GDP, GTP – guanosine diphosphate and guanosine triphosphate, respectively; GRB2 – growth factor receptor-bound protein 2; IRS – insulin receptor substrate; SHP2 – a Src homology 2 (SH2) domain containing non-transmembrane protein tyrosine phosphatase; SOS – son of sevenless, refers to a set of genes encoding guanine nucleotide exchange factors that act on the Ras subfamily of small GTPases; Src – a non-receptor cytoplasmic tyrosine kinase
Figure 3. Simplified scheme of signaling via the prolactin receptor, its long isoform (PRLR-LF) has been included for better clarity. The main signaling pathways and the typical known effects of their activation are marked in different colors. In canonical (JAK/STAT) signaling (shades of blue), ligand binding to the PRLR results in stimulation of the tyrosine kinase activity of Janus kinase 2 (JAK2) and subsequent multiple tyrosine residues phosphorylation (P) and activation of signal transducer and activator of transcription (STATs) proteins, in particular STAT5 (JAK2/STAT5 signaling) [73,74]. The lack of a physical association with STAT5a may redirect to signaling via RUSH/SMARCA3 (red) with gene regulation mainly through chromatin remodeling. The presence of transcription factors RUSH-1α and RUSH-1β as well as SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A, member 3 (SMARCA3) in both cytoplasm and nucleus suggests their bidirectional passage across the nuclear membrane (marked with a double-sided arrow with a dotted line) [76]. Transcription of target genes also occurs after activation of the Ras kinases/Raf kinases/mitogen-activated protein kinase/extracellular signal-regulated kinase ½ (Ras/Raf/MAPK/ERK1/2) [75,76] and the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3-Kinase/AKT/mTOR) [76,77] pathways. These signal paths are integrated with each other on many levels. * Activation of the PRLR may occur due to the action of agonists other than prolactin (e.g., hPL,GH, and IL-2). Other abbreviations: FAK – focal adhesion kinase; GDP, GTP – guanosine diphosphate and guanosine triphosphate, respectively; GRB2 – growth factor receptor-bound protein 2; IRS – insulin receptor substrate; SHP2 – a Src homology 2 (SH2) domain containing non-transmembrane protein tyrosine phosphatase; SOS – son of sevenless, refers to a set of genes encoding guanine nucleotide exchange factors that act on the Ras subfamily of small GTPases; Src – a non-receptor cytoplasmic tyrosine kinase
Preprints 96142 g003
Preprints 96142 g004
Figure 4. A simplified overview of the diverse functions of the prolactin receptor (PRLR) signaling through endocrine and autocrine prolactin (PRL) binding in normal and pathological conditions. APC – antigen-presenting cells, BAT – brown adipose tissue, GDM – gestational diabetes mellitus, GnRH – gonadotropin-releasing hormone (gonadoliberin), HPG axis – hypothalamic–pituitary–gonadal axis, P4 – progesterone. * associated with both hyper- and hypoprolactinemia and disorders of PRLR expression/function. In contrast to hyperprolactinemia, the most common cause of which is prolactinoma, in the vast majority of cases of hypoprolactinemia, the deficiency occurs secondary to general anterior pituitary dysfunction, as is the case in Sheenan’s syndrome (a postpartum necrosis of the pituitary gland). Isolated hypoprolactinemia is rare, and may have a genetic component (i.e., familial puerperal alactogenesis).
Figure 4. A simplified overview of the diverse functions of the prolactin receptor (PRLR) signaling through endocrine and autocrine prolactin (PRL) binding in normal and pathological conditions. APC – antigen-presenting cells, BAT – brown adipose tissue, GDM – gestational diabetes mellitus, GnRH – gonadotropin-releasing hormone (gonadoliberin), HPG axis – hypothalamic–pituitary–gonadal axis, P4 – progesterone. * associated with both hyper- and hypoprolactinemia and disorders of PRLR expression/function. In contrast to hyperprolactinemia, the most common cause of which is prolactinoma, in the vast majority of cases of hypoprolactinemia, the deficiency occurs secondary to general anterior pituitary dysfunction, as is the case in Sheenan’s syndrome (a postpartum necrosis of the pituitary gland). Isolated hypoprolactinemia is rare, and may have a genetic component (i.e., familial puerperal alactogenesis).
Preprints 96142 g004
Preprints 96142 g005
Figure 5. Folliculogenesis, ovulation and hormonal regulation of the menstrual cycle [114,115,116,117,118,119,120,121,122,123].
Figure 5. Folliculogenesis, ovulation and hormonal regulation of the menstrual cycle [114,115,116,117,118,119,120,121,122,123].
Preprints 96142 g005
Preprints 96142 g006
Figure 6. Classification of ovulatory disorders according to International Federation of Gynecology and Obstetrics – FIGO (A.) [204] and World Health Organization – WHO (B.) [206,207]. The primary level of the FIGO system is based on an anatomic model (Hypothalamus, Pituitary, Ovary) that is completed with a separate category for polycystic ovary syndrome (PCOS; the acronym HyPO-P). Each anatomic category is stratified in the second layer of the system to provide granularity for investigators, clinicians, and trainees using the “GAIN-FIT-PIE” mnemonic (Genetic, Autoimmune, Iatrogenic, Neoplasm; Functional, Infectious and Inflammatory, Trauma and Vascular; Physiological, Idiopathic, Endocrine). The tertiary level allows for specific diagnostic entities, including those related to PCOS.
Figure 6. Classification of ovulatory disorders according to International Federation of Gynecology and Obstetrics – FIGO (A.) [204] and World Health Organization – WHO (B.) [206,207]. The primary level of the FIGO system is based on an anatomic model (Hypothalamus, Pituitary, Ovary) that is completed with a separate category for polycystic ovary syndrome (PCOS; the acronym HyPO-P). Each anatomic category is stratified in the second layer of the system to provide granularity for investigators, clinicians, and trainees using the “GAIN-FIT-PIE” mnemonic (Genetic, Autoimmune, Iatrogenic, Neoplasm; Functional, Infectious and Inflammatory, Trauma and Vascular; Physiological, Idiopathic, Endocrine). The tertiary level allows for specific diagnostic entities, including those related to PCOS.
Preprints 96142 g006
Preprints 96142 g007
Figure 7. The importance of (tuberoinfundibular dopamine) TIDA, (kisspeptin/neurokinin B/dynorphin (KNDγ or KISS1) and gonadotropin-releasing hormone (GnRH)-secreting neurons in the prolactin (PRL)- and kisspeptin (KP)-dependent regulation of the hypothalamic-pituitary-gonadal (HPG) axis in females. TIDA neurons located in the arcuate nucleus (ARC) send axons towards the median eminence (ME). The tonic release of dopamine (DA) from these neuronal endings provides an appropriate level of inhibition of PRL release from lactotrophs (LTH) under physiological conditions [7]. PRLR expression in TIIDA neurons is crucial for the operation of such a short negative feedback loop in the DA/PRL system [261,262,263]. PRL in a sufficiently high concentration causes suppression of GnRH neurons that are scattered between the preoptic area (POA) and ARC in the shape of an “inverted Y” [81]. Due to the negligible expression of PRLR in GnRH neurons, the inhibitory effect of PRL is exerted indirectly, through the participation of KNDy neurons located within the ARC [12,277,278,279,280]. PRLR stimulation of KNDy neurons leads to inhibition of KP secretion, a family of polypeptides that stimulate GnRH secretion via the KP receptor (KISS-1R, also known as GPR54) in GnRH neurons [298,299,300]. PRL-dependent, limited stimulation of GnRH neurons with KP to release GnRH translates into reduced release of gonadotropins from the anterior pituitary gland with the subsequent manifestation of hypogonadotropic hypogonadism [43,297]. Hormones of ovarian origin, mainly estradiol (E2) and progesterone (P4), operating in a long negative feedback loop, influence the activity of GnRH neurons with a force proportional to their concentration in the blood. Other abbreviations: CNS – central nervous system, DYN – dynorphin, FSH – follicle-stimulating hormone, GABA – gamma-aminobutyric acid, LH – luteinizing hormone, NKB – neurokinin B
Figure 7. The importance of (tuberoinfundibular dopamine) TIDA, (kisspeptin/neurokinin B/dynorphin (KNDγ or KISS1) and gonadotropin-releasing hormone (GnRH)-secreting neurons in the prolactin (PRL)- and kisspeptin (KP)-dependent regulation of the hypothalamic-pituitary-gonadal (HPG) axis in females. TIDA neurons located in the arcuate nucleus (ARC) send axons towards the median eminence (ME). The tonic release of dopamine (DA) from these neuronal endings provides an appropriate level of inhibition of PRL release from lactotrophs (LTH) under physiological conditions [7]. PRLR expression in TIIDA neurons is crucial for the operation of such a short negative feedback loop in the DA/PRL system [261,262,263]. PRL in a sufficiently high concentration causes suppression of GnRH neurons that are scattered between the preoptic area (POA) and ARC in the shape of an “inverted Y” [81]. Due to the negligible expression of PRLR in GnRH neurons, the inhibitory effect of PRL is exerted indirectly, through the participation of KNDy neurons located within the ARC [12,277,278,279,280]. PRLR stimulation of KNDy neurons leads to inhibition of KP secretion, a family of polypeptides that stimulate GnRH secretion via the KP receptor (KISS-1R, also known as GPR54) in GnRH neurons [298,299,300]. PRL-dependent, limited stimulation of GnRH neurons with KP to release GnRH translates into reduced release of gonadotropins from the anterior pituitary gland with the subsequent manifestation of hypogonadotropic hypogonadism [43,297]. Hormones of ovarian origin, mainly estradiol (E2) and progesterone (P4), operating in a long negative feedback loop, influence the activity of GnRH neurons with a force proportional to their concentration in the blood. Other abbreviations: CNS – central nervous system, DYN – dynorphin, FSH – follicle-stimulating hormone, GABA – gamma-aminobutyric acid, LH – luteinizing hormone, NKB – neurokinin B
Preprints 96142 g007
Table 1. Expression of selected genes in individual structures of ovarian follicles during various stages of folliculogenesis. All genes were localized by in situ hybridization [124,125,126,127].
Table 1. Expression of selected genes in individual structures of ovarian follicles during various stages of folliculogenesis. All genes were localized by in situ hybridization [124,125,126,127].
CLASS/STAGE OF THE FOLLICLE EXPRESSION OF SELECTED GENES
Granulosa cells Oocyte Theca cells
Primordial 3βHSD, ALK3, BMPRII, Erβ, KITLG, StAR, WTI ALK3, ALK6, BMP6, BMPRII, C-kit, Erβ, GDF9, GJA4, TGFBR3 –
Primary βB-activin, ActRIIB, ALK6, AMH, AMHRII, FSH-R, GJA1, IGFR1 BMP15, FIGα –
Small preantral ALK5, FSRP, FST, TGFBR3 – ActRIIB, ALK3, ALK5, ALK6?, BMPRII, FSRP, IGFR1, TGF-β1, TGF-β2, TGFBR3, TGFBR11
Large preantral AR, ERα, InhA – 3βHSD, ARErβ, CYP17A1, IGF2, LHR, PR, SF1, StAR
Table 2. The main endocrine hormones involved in the control of the menstrual cycle and ovulation. Figure 5. is also helpful in the analysis of the table. * The normal values of the concentration ranges reported in the literaturę often show significant differences. Current reference values from recognized clinical centers for the treatment of menstrual cycle disorders and infertility are provided here [153,154].
Table 2. The main endocrine hormones involved in the control of the menstrual cycle and ovulation. Figure 5. is also helpful in the analysis of the table. * The normal values of the concentration ranges reported in the literaturę often show significant differences. Current reference values from recognized clinical centers for the treatment of menstrual cycle disorders and infertility are provided here [153,154].
HORMONE SOURCE TYPICAL STRUCTURE or CHEMICAL FORMULA GENERAL DESCRIPTION LEVEL CHANGES DURING THE MENSTRUAL CYCLE AND OVULATION CONCENTRATION RANGE (blood; women of reproductive age) *
Gonadotropin-releasing hormone (GnRH) Neurons of hypothalamus

Preprints 96142 i001
GnRH is a decapeptide with the presence of the amino terminal pyroglutamic acid (pE, a cyclic non-proteinogenic amino acid, containing a γ-lactam ring, that is produced from glutamine or glutamic acid by deamidation or dehydration, respectively) and the amidated carboxy terminus. In all three forms of GnRH (GnRH1, GnRH2, GnRH3), both N-terminal and C-terminal are conserved, which allows for effective binding to their receptors [114,155,156].		 The master hormone that regulates reproductive activity by stimulating the release of gonadotropins and, consequently, stimulating the production of sex hormones in the gonads. This hormone ultimately regulates puberty onset, sexual development, and ovulatory cycles in females [114,115]. Frequency and amplitude of hypothalamic GnRH pulses determine the relative proportions of pituitary secretion of FSH and LH. In the normal menstrual cycle, GnRH pulse frequency increases from about 90-100 minutes to about every 60 minutes through a follicular phase. Gradual increase in GnRH pulse frequency facilitates LH secretion culminating in an ovulatory LH surge [115,157]. Earlier, a switch from estradiol negative to positive feedback initiates the GnRH influx, affecting LH release. In contrast, increased progesterone secretion in a luteal phase results in an increase in FSH synthesis as a result of less frequent hypothalamic GnRH secretion (approximately one pulse every 3–5 hours), through mechanisms involving opioid receptors [158,159,160,161] and possibly other factors such as kisspeptin [162]. Approx., 0.1 – 2.0 pg/ml; the basal levels of GnRH do not change significantly before, during and after the LH surges, and show fluctuations (pulsations) between a small range of 0.1 and 2.0 pg/ml [163].
Follicle-stimulating hormone (FSH) Anterior pituitary Preprints 96142 i002
FSH is a 35,5 kDa glycoprotein heterodimer, consisting of two non-covalently linked polypeptide subunits: the alpha subunit (92 aa), which is common to all glycoprotein hormones, and a unique beta subunit (111 aa), providing specificity of action. FSH structure is similar to those of luteinizing hormone (LH), thyroid-stimulating hormone (TSH), and human chorionic gonadotropin (hCG) [164]. Each subunit contains two asparagine-linked N-glycosylation sites (N-linked NGlyS): N52 and N78 within the α subunit, and N7 and N24 within the β subunit [165]. Based on the number of occupied N-glycosylation sites, four human FSH glycoforms have been identified: hFSH24, which possesses N-glycans at all four sites; hFSH21, which lacks the βAsn24 glycan; hFSH18, which lacks the βAsn7 glycan; and hFSH15, which lacks both FSHβ N-glycans. The two most abundant human FSH glycoforms are FSH24 and FSH21 [166].		 Produced in response to GnRH, FSH plays a central role in reproduction. In females, FSH stimulates antrum formation in secondary follicles, growth and maturation in antral follicles, and it prepares the latter for ovulation in response to the LH surge [116]. FSH stimulates granulosa cells in the ovarian follicles to synthesize aromatase, which converts androgens produced by the thecal cells to estradiol [E2]. In the presence of estradiol, FSH stimulates the formation of LH receptors on granulosa cells allowing for the secretion of small quantities of progesterone and 17-hydroxyprogesterone (17-OHP) which may exert a positive feedback on the estrogen- primed pituitary to augment LH release [117,167,168]. Declining steroid production by the corpus luteum and the dramatic fall of inhibin A allows for FSH to rise during the last few days of the menstrual cycle. Another influential factor on the FSH level in the late luteal phase is related to an increase in GnRH pulsatile secretion secondary to a decline in both E2 progesterone (P4) levels. This elevation in FSH allows for the recruitment of a cohort of ovarian follicles in each ovary, one of which is destined to ovulate during the next menstrual cycle [116]. Increasing FSH levels during the late luteal phase leads to an increase in the number of FSH receptors (FSHRs) and ultimately to an increase in estradiol secretion by granulosa cells. It is important to note that the increase in FSHR numbers is due to an increase in the population of granulosa cells and not due to an increase in the concentration of FSHR per granulosa cell. Each granulosa cell has approximately 1500 FSHRs by the secondary stage of follicular development and FSHR numbers remains relatively constant for the remainder of development [169].Once menses ensues, FSH levels begin to decline due to the negative feedback of estrogen and the negative effects of inhibin B produced by the developing follicle (Figure 5) [117]. Early follicular 3-10 (IU/L); mid-cycle peak 4-25; pregnancy < 1
Luteinizing hormone (LH) Anterior pituitary Preprints 96142 i003
Human LH is a 29,0 kDa glycoprotein heterodimer, consisting of two non-covalently linked polypeptide subunits: the alpha subunit (92 aa), which is common to all glycoprotein hormones (including FSH, and hCG, and TSH), and a unique beta subunit (120 aa) that confers its specific biological action. β-subunit of LH contains an amino acid sequence that exhibits large homologies with that of the beta subunit of hCG and both stimulate the same receptor. However, the hCG beta subunit contains an additional 24 amino acids, and the two hormones differ in the composition of their sugar moieties that affects bioactivity and half-life. There are three asparagine-linked N-glycosylation sites (N-linked NGlyS): N52 and N78 within the α subunit, and only one carbohydrate attachment site (N-linked NGlyS) within the β subunit [118,170].		 LH is essential to provide the androgen substrate for estrogen synthesis, which in turn contributes to oocyte maturation and may play a relevant role in optimizing fertilization and embryo quality [118,171]. LH helps to regulate the length and order of the menstrual cycle by playing roles in both ovulation and implantation of an egg in the uterus [168,172]. Unlike FSH, LH concentration is low during the early follicular phase and begins to rise by the mid-follicular phase due to the positive feedback from the rising estrogen levels. For the positive feedback effect of LH release to occur, estradiol levels must be greater than 200 pg/mL for approximately 50 hours in duration [117]. The midcycle gonadotropin (FSH, LH) surge marks the end of the follicular phase of the cycle and precedes actual rupture by as much as 36 hours. During this surge, LH levels are highest about 10-12 hours before ovulation and can reach 30 IU/L or higher. The LH surge stimulates luteinization of the granulosa cells and stimulates the synthesis of progesterone responsible for the midcycle FSH surge. Also, the LH surge stimulates resumption of meiosis and the completion of reduction division in the oocyte with the release of the first polar body. LH and progesterone cause an increase in the activity of prostaglandins and proteolytic enzymes (e.g. collagenase, plasmin) involved in the mechanism of follicle wall rupture with release of the oocyte-cumulus of the granulosa cells complex [118,173]. After ovulation the remaining theca and granulosa cells in the crater of the ovulated follicle organize into a progestero-ne-secreting corpus luteum, active for about 2 weeks, after which it regresses in the absence of pregnancy (Figure 5). Early follicular 1,5-9 (IU/L); mid-cycle peak (before ovulation) 6,2-35; weeks 3 and 4 of the menstrual cycle: 1-9,2; pregnancy < 2-9
Estrogens Ovaries (ovarian follicles) Preprints 96142 i004

Chemically, estrogens are derivatives of cholesterol, an organic compound belonging to the steroid family. There are three major endogenous estrogens that have estrogenic hormonal activity: estrone (E1), estradiol (E2), and estriol (E3). Another type of estrogen called estetrol (E4) is produced only during pregnancy. Steroid sex hormone estradiol (E2; 17β-estradiol) is the most abundant and active estrogen in women of reproductive age (between the menarche and menopause) [174]. In females, estrogens are produced by locally expressed p450 aromatase from follicular androgens in the ovary and other estrogen-responsive tissues [175].		 Estrogen is one of the most impactful hormones in the body. Estrogen is responsible for the stimulation of secondary female characteristics (body composition, breast development, menstrual cycle, etc.). It can also impact other aspects of health such as control of metabolism (e.g., bone mineral density, cholesterol level), mood stability, immune system function, complexion, and carcinogenesis [176,177,178,179]. Estrogens are produced primarily by the ovaries. They are released by the follicles on the ovaries and are also secreted by the corpus luteum after the oocyte has been released from the follicle. During pregnancy, the placenta is an important source of estrogens [180]. Estrogen (predominantly E2) levels rise and fall twice during the menstrual cycle. Estrogen levels rise during the mid-follicular phase and then drop precipitously after ovulation. This is followed by a secondary rise in estrogen levels during the mid-luteal phase with a decrease at the end of the menstrual cycle (Figure 5) [117]. Early follicular < 300 pmol/L; ovulatory surge 500-3000 pmol/L; luteal surge 100-1400 pm/L
Progesterone (P4) Ovaries (corpus luteum) Preprints 96142 i005

In mammals,P4, like all other steroid hormones, is synthesized from pregnenolone, which itself is derived from cholesterol. P4 biosynthesis requires only two enzymatic steps; the conversion of cholesterol to pregnenolone, catalyzed by P450 side chain cleavage (P450scc) located on the inner mitochondrial membrane, and its subsequent conversion to progesterone, catalyzed by 3β-hydroxysteroid dehydrogenase (3β-HSD) present in the smooth endoplasmic reticulum (SER) [181].		 The synthesis of progesterone by the corpus luteum (luteinized granulosa and theca cells) is essential for the establishment and maintenance of early pregnancy (decidualization of the endometrium) [182]. In the following weeks of pregnancy (after the 10th week of pregnancy), the placenta becomes the main source of progesterone [183]. P4 levels are low during the follicular phase, and they rise after ovulation during the luteal phase, with the possibility of further maintenance and increase of P4 biosynthesis as a result of stimulation with chorionic gonadotropin (hCG) after blastocyst implantation [119]. Follicular phase : <0,181 to 2,84nmol/L; luteal phase: 5.82 – 75,9 nmol/L;
Detecting ovulation – measured on day 20 – 23 of a normal 28 day cycle: >25 nmol/L ovulation likely;7-25 nmol/L – ovulation possible; 0-6 nmol/L – ovulation unlikely
Inhibins Ovaries (ovarian follicles: granulosa and theca cells) Preprints 96142 i006
Inhibins are heterodimeric glycoproteins composed of an α-subunit and one of two β-subunits, forming inhibin A (αβA) and inhibin B (αβB). The respective subunits are linked via a single disulfide bond. The α-and β-subunits are produced as larger precursor proteins, prepro-α, pro-βA and pro-βB, that include a signal peptide and pro-region, both of which are cleaved to form the mature α or β-subunit [120,184,185]. Inhibins, similarly to activins that have opposing effects on FSH secretion, belong to the transforming growth factor-beta (TGF-β) superfamily of multifunctional cytokines [121].		 The activins and inhibins are among the 33 members of the TGF-β superfamily and were first described as regulators of follicle-stimulating hormone (FSH) secretion and erythropoiesis. It is now known that these cytokines participate in the regulation of various processes, ranging from the early stages of embryonic development, to highly specialized functions in terminally differentiated cells and tissues that maintain homeostasis [121,186,187,188]. The biological effects of TGF-β family proteins, including inhibins, are contextual, and even the same cell type may show different or opposite responses to the ligand under different biological contexts. It is, therefore, possible that the heterogeneity could contribute to different responsiveness to TGF-β family members [189]. In female individuals, inhibin A is primarily produced by the dominant follicle and corpus luteum; whereas inhibin B is predominantly produced by small developing follicles. The negative feedback control of pituitary FSH secretion has been the most recognized physiological role of inhibins. They selectively suppress secretion of pituitary follicle stimulating hormone (FSH) and have local paracrine actions in the gonads [117,122,190]. Serum inhibin A and B levels fluctuate during the menstrual cycle. Inhibin B dominates the follicular phase of the cycle, while Inhibin A dominates the luteal phase. This means that serum inhibin B levels increase early in the follicular phase to reach a peak coincident with the onset of the decline in FSH levels at the midfollicular phase, whereas inhibin A levels are low in the early follicular phase and rise at ovulation to maximum levels in the midluteal phase of the menstrual cycle (Figure 5). Once menses ensues, FSH levels begin to decline due to the negative feedback of estrogen and the negative effects of inhibin B produced by the developing follicle [123,191]. 2-80 pg/mL: 2-10 pg/mL in the follicular phase, 40-80 pg/mL in the luteal phase
Table 3. Causes of hyperprolactinemia.
Table 3. Causes of hyperprolactinemia.
Category of hyperprolactinemia Examples, incl. medications Possible etiology (direct cause, if known)
PHYSIOLOGICAL Pregnancy and postpartum
Breast feeding (nipple stimulation, suckling)
Nursing 		Reduced dopamine secretion from tuberoinfundibular dopamine (TIDA) neurons of the arcuate nucleus in the hypothalamus and disappearance of the negative-feedback mechanism between PRL and TIDA activity, resulting in unresponsiveness of TIDA to increased PRL concentration [223].
Stress Complex neuroendocrine response to physical and emotional distress reduces PRL signaling in TIDA neurons and thus potentially a decline in their inhibitory dopamine-dependent influence on PRL secretion [224].
Exercise, especially high intensity Hypothalamic thyrotropin-releasing hormone (TRH) release caused by physical exercise stimulates both release of thyroid-stimulating hormone (TSH) and thus the production of thyroid hormones as well as the release of PRL from lactotrophic cells [225].
Sleep Unspecified connection with the sleep-wake cycle [226].
Chest wall stimulation Neurogenic. It is hypothesized that even indirect stimulation of the intercostal nerves may result in induction of an stimulatory reflex conducted by intercostal nerves with subsequent stimulation of hypothalamic centers controlling lactation [227].
Food ingestion Probably because PRL signaling is implicated in the regulation of glucose homeostatic adaptations through its impact in pancreatic islet cell physiology and glucose metabolism [228].
Sexual intercourse PRL increases following orgasm are involved in a feedback loop that serves to decrease arousal through inhibitory central dopaminergic and probably peripheral processes [229].
PATHOLOGICAL Pituitary disease:
- Pituitary tumors: prolactinomas, mixed GH/PRL or adrenocorticotropic hormone (ACTH)/PRL – secreting adenomas, intrasellar non-secretory tumors causing stalk compression (non-functioning adenomas, germinoma, meningioma, glioma, metastasis)
- Hypophyseal stalk lesion (“stalk effect”)
- Hypophysitis (inflammation of hypophyseal stalk, e.g. lymphocytic hypophysitis) primary or secondary to a local or systemic process
- Hypothalamic and pituitary stalk disease: granulomatous disease (sarcoidosis, tuberculosis, eosinophilic granuloma), tumors (craniopharyngioma, hamartoma, glioma, germinoma, metastasis), cranial irradiation, pituitary stalk section, empty sella syndrome (empty pituitary fossa), vascular (aneurysm, arteriovenous malformation)		 Differential diagnosis is broad (including primary tumors, metastases, and lympho-proliferative diseases) and multifaceted.
Excessive production of PRL by hypertrophic or neoplastic pituitary tissue and/or disinhibition of lactotrophs due to mechanical interruption of the portal transport of dopamine from the hypothalamus to the anterior pituitary gland (stalk effect) [81,230].
Primary hypothyroidism Increased levels of TRH can cause to rise PRL levels by stimulation of TRH receptors on lactotrophic cells [231].
Chronic renal insufficiency Reduction in metabolic clearance of PRL and direct stimulation of PRL secretion from lactotrophs due to reduced availability of dopamine in the brain in the uremic state [232,233].
Severe liver failure (inc. cirrhosis) Decompensated liver function leads to an alteration in the type of amino acids entering the central nervous system with an increase in the synthesis of false neurotransmitters such as octopamine and phenylethanolamine. These false neurotransmitters may inhibit the dopamine release contributing to hyperprolactinemia [234].
Neuraxis irradiation (radiation therapy) Hyperprolactinemia may develop in 20-50% of cases after high dose (> 50 Gy) cranial radiotherapy as a result of hypothalamic damage and reduced inhibitory dopamine activity [235]. Elevated PRL levels may decline and normalize during follow-up due to radiation-induced reduction of the pituitary lactotroph cells [236].
Spinal cord lesions Secondary hyperprolactinemia due to elevated endorphins and opioid phenotypes in the central nervous system (CNS) following spinal cord injury-related shock as well as production of PRL-releasing factors [237,238,239].
Seizures Activation of certain pathways in the brain that regulate PRL secretion or the activation of the hypothalamic-pituitary-adrenal (HPA) axis, which can subsequently increase PRL levels in the blood [240].
Polycystic ovary syndrome (PCOS) Probably secondary to increased E2 levels and/or insulin-resistance in PCOS patients [215,241].
Ectopic secretion of PRL (bronchogenic carcinoma, hypernephroma) Excess PRL from tumor tissue not subject to negative feedback regulation by dopamine [242].
Chest wall trauma (including surgery, herpes zoster) A damage or sectioning of the intercostal nerves may result in reflex stimulation of hypothalamic centers controlling lactation through the same neural pathways involved in puerperal lactation [243].
Idiopathic Unknown cause or no clear cause
PHARMACOLOGICAL (iatrogenic) Typical antipsychotics: haloperidol, phenothiazines, thioridazine, clomipramine, fluphenazine, pimozide, prochlorperazine
PRL-raising atypical antipsychotics: risperidone, olanzapine, molindone, paliperidone		 Antipsychotic-associated dopamine D2 receptor antagonism. Blockade of D2 by typical antipsychotics and risperidone can cause hyperprolactinemia [244,245].
Atypical antipsychotics other than risperidone are less likely to cause sustained hyperprolactinemia; asymptomatic and transient hyperprolactinemia is more common, because of their lower affinity for D2 receptors [246].
Antidepressant agents:
selective serotonin reuptake inhibitors – SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine); tricyclic antidepressants – TCAs (amitriptyline, amoxapine, clomipramine, desipramine);
monoamine oxidase inhibitors – MAOIs (clorgyline, pargyline)
Inhibition of the tuberoinfundibular dopaminergic (D2) pathway through stimulation of gamma aminobutyric acid (GABA)ergic neurons and release of PRL-regulating factors, such as vasoactive intestinal peptide (VIP) or oxytocin [247,248].

May cause indirect modulation of PRL release by increasing serotonin (5-HT) [249].
Gastrointestinal drugs: metoclopramide, domperidone, prochlorperazine,
metiamide, cimetidine (intravenous)		 Dopamine D2 receptor antagonism [250].
Cimetidine, a histamine H2 receptor antagonist acting in the hypothalamus inhibits dopamine secretion, as well as increases 5-HT release within dopamine-GABA-serotoninergic system [249,251,252].
Antihypertensive agents:
- methyldopa,


- verapamil,
- reserpine, tetrabenazine
Alpha-methyldopa causes hyperprolactinemia by inhibiting the enzyme l-aromatic amino acid decarboxylase (which is responsible for converting L-dopa to dopamine) and by acting as a false neurotransmitter to decrease dopamine synthesis [253].
Verapamil, a phenylalkylamine calcium channel blocker, blocks hypothalamic (tuberoinfundibular) production of dopamine [254].
Reserpine and tetrabenazine produce a reversible depletion of dopamine by inhibition of the vesicular monoamine transporter type-2 (VMAT2) that blocks dopamine storage in synaptic vesicles of neurons [255,256].
Opiates: codeine, morphine Disinhibition of lactotrophs by the inhibitory effect of TIDA neurons (decreased dopaminergic activity due to decrease in the turnover and release of hypothalamic dopamine) [257,258].
Hormone preparations: antiandrogens, combined oral contraceptives, estrogens Estrogen-stimulated lactotroph hyperplasia [259,260].
ANALYTICAL (assay artefacts) - misdiagnosis Macroprolactin Macroprolactinemia represents a state of hyperprolactinemia characterized by the predominance of macroprolactin (also known as big–big PRL), a macromolecule with limited bioavailability and bioactivity, and it is mainly suspected in asymptomatic individuals or those without the typical hyperprolactinemia-related symptoms. [52,55,222].
Heterophilic antibodies (endogenous proteins that bind animal antigens) Heterophilic antibodies interact poorly and nonspecifically with the assay antibodies. Depending on the type of such antibody and the immunoassay format, heterophilic antibodies can lead to both falsely high and low analyte concentrations according to the site of interference [222].
Prozone phenomenon (hook effect), i.e., falsely normal or mildly elevated PRL while the true PRL concentration is many fold higher than the upper limit This phenomenon occurs when extremely high PRL concentration (i.e., observed in large pituitary macroadenomas [≥3 cm]) saturates both the capture and the labeled antibody during immunoassay, preventing the formation of the “sandwich” and causing false-negative results [222].
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated